```
=> b reg
FILE 'REGISTRY' ENTERED AT 11:20:16 ON 23 SEP 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   22 SEP 2008  HIGHEST RN 1051655-89-0
DICTIONARY FILE UPDATES:  22 SEP 2008  HIGHEST RN 1051655-89-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=> d que sta l8
L4              STR
```




```
VAR G1=9-2 10-6/11-6 12-2
REP G2=(1-4) C
VAR G3=O/S
REP G4=(1-6) C
REP G5=(0-5) C
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS  18

STEREO ATTRIBUTES: NONE
L6      1987968 SEA FILE=REGISTRY ABB=ON  PLU=ON  14-17/RATC
L8          698 SEA FILE=REGISTRY SUB=L6 SSS FUL L4

100.0% PROCESSED  768346 ITERATIONS                          698 ANSWERS
SEARCH TIME: 00.00.16



=> d que sta l12
L12             STR
```



VAR G1=9-2 10-6/11-6 12-2
REP G2=(1-4) C
VAR G3=O/S
REP G4=(1-6) C
REP G5=(0-5) C
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 19

STEREO ATTRIBUTES: NONE

=> d que sta l21
L4 STR



VAR G1=9-2 10-6/11-6 12-2
REP G2=(1-4) C
VAR G3=O/S
REP G4=(1-6) C
REP G5=(0-5) C
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 18

STEREO ATTRIBUTES: NONE
L6 1987968 SEA FILE=REGISTRY ABB=ON PLU=ON 14-17/RATC
L8 698 SEA FILE=REGISTRY SUB=L6 SSS FUL L4
L19 STR



VAR G1=9-2 10-6/11-6 12-2
REP G2=(1-4) C
VAR G3=O/S
REP G4=(1-6) C
REP G5=(0-5) C
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 20

STEREO ATTRIBUTES: NONE
L21 188 SEA FILE=REGISTRY SUB=L8 SSS FUL L19

100.0% PROCESSED 698 ITERATIONS 188 ANSWERS
SEARCH TIME: 00.00.01

=> b hcap
FILE 'HCAPLUS' ENTERED AT 11:20:38 ON 23 SEP 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 23 Sep 2008 VOL 149 ISS 13
FILE LAST UPDATED: 22 Sep 2008 (20080922/ED)

HCAplus now includes complete International Patent Classification (IPC)
reclassification data for the second quarter of 2008.

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate
substance identification.

=> => d bib abs hitstr l38 tot

L38 ANSWER 1 OF 2 HCAPLUS COPYRIGHT 2008 ACS on STN
AN 2008:90973 HCAPLUS
DN 148:191967
TI Preparation of macrocyclic compounds useful as BACE inhibitors
IN Machauer, Rainer
PA Novartis AG, Switz.; Novartis Pharma GmbH
SO PCT Int. Appl., 35pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO--2008009734	A1	20080124	2007WO-EP057492	20070719
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
PRAI 2006EP-000117583	A	20060720		
OS MARPAT 148:191967				

GI



I



II

AB Title compds. represented by the formula I [wherein R1 = (CH2)kNRaRb; k = 0-2; Ra = H, (un)substituted alkyl, aryl, etc.; Rb = (un)substituted cycloalkyl; R2 = H or alkyl; R3 = H, alkyl, (un)substituted alkyl-OC(O)NH, etc.; U = a bond, CF2, CF2CF2, etc.; V = CH:CH, cyclopropylene, CH2CH(OH), etc.; V1 = H; V2 = OH; W = alkylene, O, S, SO2, etc.; X = (un)substituted (cyclo)alkylene, piperidinyl or pyrrolidinyl; Y = a bond, O, SO2, etc.; Z = O, CH2, OF2, etc.; n = 0-5, the number of ring atoms included in the macrocyclic ring being 14, 15, 16 or 17; in free base form or in acid addition salt form] were prepared as BACE inhibitors. For example, II was provided in a multi-step synthesis starting from tert-Bu [(S)-1-[[(1S,3R)-1-((1S)-2-chloro-1-hydroxyethyl)-3-methylhept-6-enyl]carbamoyl]ethyl](methyl)carbamate. II showed inhibition of human BACE with IC50 value of 0.03 μM. Thus, I and their pharmaceutical

L38 ANSWER 1 OF 2 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)
comps. are useful for the treatment of neurol. or vascular disorders related to β-amyloid generation and/or aggregation.
IT 852877-45-3P, (3S,14R,16S)-16-((S)-2-Chloro-1-hydroxyethyl)-3,4,14-trimethyl-1,4-diazacyclohexadecane-2,5-dione
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of macrocyclic compds. useful as BACE inhibitors)
RN 852877-45-3 HCAPLUS
CN 1,4-Diazacyclohexadecane-2,5-dione, 16-[(1S)-2-chloro-1-hydroxyethyl]-3,4,14-trimethyl-, (3S,14R,16S)- (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L38 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2008 ACS on STN
AN 2005:472134 HCAPLUS
DN 143:26648
TI Preparation of macrocyclic lactams for treatment of neurological or vascular disorders related to β-amyloid generation and/or aggregation
IN Auberson, Yves; Betschart, Claudia; Glatthar, Ralf; Laumen, Kurt; Machauer, Rainer; Tintelnot-Blomley, Marina; Troxler, Thomas J.; Veenstra, Siem Jacob
PA Novartis A.-G., Switz.; Novartis Pharma G.m.b.H.
SO PCT Int. Appl., 84 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO--2005049585	A1	20050602	2004WO-EP0012497	20041104
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU--2004291276	A1	20050602	2004AU-000291276	20041104
CA-----2544751	A1	20050602	2004CA-002544751	20041104
EP-----1682521	A1	20060726	2004EP-000797621	20041104
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS				
BR--2004016276	A	20070123	2004BR-000016276	20041104
CN-----1902182	A	20070124	2004CN-080039425	20041104
JP--2007510002	T	20070419	2006JP-000538745	20041104
MX-2006PA05032	A	20060706	2006MX-PA005032	20060504
IN-2006CN01527	A	20070706	2006IN-CN0001527	20060504
US-20070072792	A1	20070329	2006US-000577260	20060602
PRAI 2003GB-000025830	A	20031105		
2004WO-EP0012497	W	20041104		
OS MARPAT 143:26648				

GI



I



II

AB The present invention relates to novel macrocyclic compds. of the formula (I) [R1 = each N-(un)substituted CH(Re)C(O)NH2 or (CH2)kNH2 (wherein k = 0-2); R2 = H, C1-4 alkyl; R3 = H, C1-6 alkyl, (un)substituted C1-6 alkyl-OC(O)NH, C3-7 cycloalkyl-OC(O)NH, C3-7 cycloalkyl-C1-4 alkyl-OC(O)NH, aryl-C1-4 alkyl-OC(O)NH, heteroaryl-C1-4 alkyl-OC(O)NH, C1-4 alkyl-C(O)NH, C3-7-cycloalkylC(O)NH, aryl-C(O)NH, aryl-C1-4 alkyl-C(O)NH, heteroaryl-C(O)NH, heteroaryl-C1-4 alkyl-C(O)NH; U = a bond, CF2, CF2CF2, CHF, CHFCHF, cycloprop-1,2-ylene, C1-3 alkylenoxy, C1-8 alkylene, each (un)substituted NH or an arom. or heteroarom. ring whereby Z and V are in ortho- or meta-position to each other; V = CH:CH, cycloprop-1,2-ylene, CH2CH(OH), CH(OH)CH2, CRhRhCRhRh (wherein Rh = independently H, F, (C:)alkyl); W = C1-6 alkylene, O, S, S(O)2, C(O), C(O)O, OC(O), each (un)substituted NHC(O), C(O)NH, or NH whereby Y and (un)substituted C(O)NH are in meta-position to each other; Y = a bond, O, S(O)2, each (un)substituted S(O)2NH, NHS(O)2, NH, CHOH, C(O)NH, NHC(O), C(O)NHO, or ONHC(O); Z = O, CH2, OF2, CHF, cycloprop-1,2-ylene, a bond; n = 0-5, the no. of ring atoms included in the macrocyclic ring being 14, 15, 16 or 17, in free base form or in acid addn. salt form]. These compds. are useful as pharmaceuticals for the treatment of neurol. or vascular disorders related to β-amyloid generation and/or aggregation which may include neurodegenerative diseases like Alzheimer's disease, Down's Syndrome, memory and cognitive impairment, dementia, amyloid neuropathies, brain inflammation, nerve and brain trauma, vascular amyloidosis, or cerebral hemorrhage with amyloidosis. They inhibit BACE2 (beta-site APP-cleaving enzyme 2) (β-Secretase 2) or cathepsin D, close homologs of the pepsin-type aspartyl proteases and of β-secretase and can be used for the treatment of disorders involving processing by such enzymes. Particularly they inhibit β-secretase and as such inhibit the generation of β-amyloid and the subsequent aggregation into oligomers and fibrils. Thus ring-closing metathesis of hept-6-enoic acid N-[(S)-1-[[(R)-1-(2-chloro-1-hydroxyethyl)-3-methylhept-6-enyl]carbamoyl]ethyl]-N-methylamide in the presence of [1,3-bis(2,4,6-trimethylphenyl)-2-imidazolidinylidene]dichloro(phenylmethylene)-(tricyclohexylphosphine)ruthenium (Grubbs II catalyst) in CH2Cl2 under refluxing gave (E)-(3S,14R)-16-(2-Chloro-1-hydroxyethyl)-3,4,14-trimethyl-1,4-diazacyclohexadec-10-ene-2,5-dione which was hydrogenated over 10% Pd-C in ethanol to give (3S,14R)-16-(2-chloro-1-hydroxyethyl)-3,4,14-trimethyl-1,4-diazacyclohexadecane-2,5-dione (II). Cyclization of II by treatment with a mixt. of aq. 1 M NaOH and THF at 0° for 2 h gave (3S,14R)-3,4,14-trimethyl-16-(oxiran-2-yl)-1,4-diazacyclohexadecane-2,5-dione which underwent amination with 3-methylbenzylamine at 65° for 2 h to give (3S,14R)-16-[1-hydroxy-2-(3-methylbenzylamino)ethyl]-3,4,14-trimethyl-1,4-diazacyclohexadecane-2,5-dione. The compds. II showed inhibitory activity of <20 μM in at least one of assays on human BACE, BACE-2, cathepsin D, and cellular release of amyloid peptide 1-40.

L38 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)
IT 852877-28-2P, (3S,14R)-16-(2-Chloro-1-hydroxyethyl)-3,4,14-trimethyl-1,4-diazacyclohexadecane-2,5-dione 852877-29-3P, (E)-(3S,14R)-16-(2-Chloro-1-hydroxyethyl)-3,4,14-trimethyl-1,4-diazacyclohexadec-10-ene-2,5-dione 852877-84-0P, [(3S,6S,14R,16S)-16-[(1S,3R)-3-(Butylcarbamoyl)-1-hydroxybutyl]-3,14-dimethyl-2,5-dioxo-1,4-diazacyclohexadec-10-en-6-yl]carbamic acid tert-butyl ester
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of macrocyclic lactams for treatment of neurol. or vascular disorders related to β-amyloid generation and/or aggregation)
RN 852877-28-2 HCAPLUS
CN 1,4-Diazacyclohexadecane-2,5-dione, 16-(2-chloro-1-hydroxyethyl)-3,4,14-trimethyl-, (3S,14R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 852877-29-3 HCAPLUS
CN 1,4-Diazacyclohexadec-10-ene-2,5-dione, 16-(2-chloro-1-hydroxyethyl)-

L38 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)
3,4,14-trimethyl-, (3S,10E,14R)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 852877-84-0 HCAPLUS
CN Carbamic acid, [(3S,6S,14R,16S)-16-[(1S,3R)-4-(butylamino)-1-hydroxy-3-methyl-4-oxobutyl]-3,14-dimethyl-2,5-dioxo-1,4-diazacyclohexadec-10-en-6-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



IT 852877-26-0P, (3S,14R)-16-[1-Hydroxy-2-(3-methylbenzylamino)ethyl]-3,4,14-trimethyl-1,4-diazacyclohexadecane-2,5-dione 852877-37-3P, (3S,14R)-16-[1-Hydroxy-2-(3-methoxybenzylamino)ethyl]-3,4,14-trimethyl-1,4-diazacyclohexadecane-2,5-dione 852877-38-4P, (3S,14R)-16-[1-Hydroxy-2-[[2-(pyridin-4-yl)ethyl]amino]ethyl]-3,4,14-trimethyl-1,4-diazacyclohexadecane-2,5-dione 852877-39-5P, (3S,14R)-16-[2-[[2-(3,4-Dimethoxyphenyl)ethyl]amino]-1-hydroxyethyl]-3,4,14-trimethyl-1,4-diazacyclohexadecane-2,5-dione 852877-40-8P, (3S,14R)-16-[1-Hydroxy-2-(3-methylbenzylamino)ethyl]-3,14-dimethyl-1,4-diazacyclohexadecane-2,5-dione 852877-41-9P, (3S,14R)-16-[1-Hydroxy-2-(3-methoxybenzylamino)ethyl]-3,14-dimethyl-1,4-diazacyclohexadecane-2,5-dione 852877-42-0P, (3S,14R)-16-[1-Hydroxy-2-(3-isopropylbenzylamino)ethyl]-3,14-dimethyl-1,4-diazacyclohexadecane-2,5-dione 852877-43-1P, (3S,14R)-16-[1-Hydroxy-2-[[2-(pyridin-4-yl)ethyl]amino]ethyl]-3,14-dimethyl-1,4-diazacyclohexadecane-2,5-dione 852877-44-2P, (3S,14R,16S)-16-[(1R)-1-Hydroxy-2-(3-isopropylbenzylamino)ethyl]-3,4,14-trimethyl-1,4-diazacyclohexadecane-2,5-dione 852877-64-6P, (3S,14R,16S)-16-[(1R)-2-(3-Cyclopropylbenzylamino)-1-hydroxyethyl]-3,4,14-trimethyl-1,4-diazacyclohexadecane-2,5-dione 852877-65-7P, (3S,14R,16S)-16-[(1R)-2-[(5-Bromopyridin-3-ylmethyl)amino]-1-hydroxyethyl]-3,4,14-trimethyl-1,4-diazacyclohexadecane-2,5-dione 852877-66-8P, (3S,14R,16S)-16-[(1R)-2-[(5-Cyclopropylpyridin-3-ylmethyl)amino]-1-hydroxyethyl]-3,4,14-trimethyl-1,4-diazacyclohexadecane-2,5-dione 852877-67-9P, (3S,14R,16S)-16-[(1R)-2-[(2-Cyclopropylpyridin-4-ylmethyl)amino]-1-hydroxyethyl]-3,4,14-trimethyl-1,4-diazacyclohexadecane-2,5-dione 852877-68-0P, (3S,14R,16S)-16-[(1R)-2-(2,2-Dimethyl-6-isopropylchroman-4-ylamino)-1-hydroxyethyl]-3,4,14-trimethyl-1,4-diazacyclohexadecane-2,5-dione 852877-69-1P, (3S,14R,16S)-16-[(1R)-2-(3-tert-Butylbenzylamino)-1-hydroxyethyl]-3,4,14-trimethyl-1,4-diazacyclohexadecane-2,5-dione 852877-70-4P, (3S,14R,16S)-16-[(1R)-2-[[3-(2,2-Dimethylpropyl)benzyl]amino]-1-hydroxyethyl]-3,4,14-trimethyl-1,4-diazacyclohexadecane-2,5-dione 852877-71-5P, (3S,15R,17S)-17-[(1R)-1-Hydroxy-2-[(3-

L38 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)
isopropylbenzyl)amino]ethyl]-3,4,15-trimethyl-1,4-diazacycloheptadecane-2,5-dione 852877-73-7P, (3S,8S,14R,16S)-16-[(1R)-1-Hydroxy-2-(3-isopropylbenzylamino)ethyl]-3,4,8,14-tetramethyl-1,4-diazacyclohexadecane-2,5-dione 852877-94-2P, (2R,4S)-N-Butyl-4-((2S,5S,7R)-2,7-dimethyl-3,15-dioxo-1,4-diazacyclopentadecan-5-yl)-4-hydroxy-2-methylbutanamide 852877-95-3P, (2R,4S)-N-Butyl-4-((2S,5S,7R)-2,7-dimethyl-3,16-dioxo-1,4-diazacyclohexadecan-5-yl)-4-hydroxy-2-methylbutanamide 852877-96-4P 852877-97-5P, [(3S,6S,12R,14S)-14-[(1S,3R)-3-(Butylcarbamoyl)-1-hydroxybutyl]-3,12-dimethyl-2,5-dioxo-1,4-diazacyclotetradecan-6-yl]carbamic acid tert-butyl ester 852877-98-6P, (2R,4S)-N-Butyl-4-((2S,5S,7R)-2,7-dimethyl-3,14-dioxo-1,4-diazacyclotetradecan-5-yl)-4-hydroxy-2-methylbutanamide 852878-03-6P, (2R,4S)-N-Butyl-4-hydroxy-2-methyl-4-((2S,5S,7R)-1,2,7-trimethyl-3,15-dioxo-1,4-diazacyclopentadecan-5-yl)butanamide 852878-04-7P, (2R,4S)-N-Butyl-4-hydroxy-2-methyl-4-((2S,5S,7R)-1,2,7-trimethyl-3,16-dioxo-1,4-diazacyclohexadecan-5-yl)butanamide 852878-05-8P, (2R,4S)-N-Butyl-4-hydroxy-2-methyl-4-((2S,5S,7R)-1,2,7-trimethyl-3,17-dioxo-1,4-diazacycloheptadecan-5-yl)butanamide 852878-08-1P, (2R,4S)-N-Butyl-4-hydroxy-2-methyl-4-((2S,5S,7R,13S)-1,2,7,13-tetramethyl-3,16-dioxo-1,4-diazacyclohexadecan-5-yl)butanamide 852878-09-2P, (2R,4S)-N-Butyl-4-hydroxy-2-methyl-4-((2S,5S,7R,13R)-1,2,7,13-tetramethyl-3,16-dioxo-1,4-diazacyclohexadecan-5-yl)butanamide 852878-10-5P, (2R,4S)-N-Butyl-4-hydroxy-2-methyl-4-((2S,5S,7R,14R)-1,2,7,14-tetramethyl-3,16-dioxo-1,4-diazacyclohexadecan-5-yl)butanamide 852878-25-2P, (2R,4S)-N-Butyl-4-hydroxy-2-methyl-4-((2S,5S,7R,12R)-2,7,12-trimethyl-3,15-dioxo-1,4-diazacyclopentadecan-5-yl)butanamide 852878-26-3P, (2R,4S)-N-Butyl-4-hydroxy-2-methyl-4-((2S,5S,7R,12S)-2,7,12-trimethyl-3,15-dioxo-1,4-diazacyclopentadecan-5-yl)butanamide 852878-27-4P 852878-28-5P, N-[(3S,6S,14R,16S)-16-[(1S,3R)-3-(Butylcarbamoyl)-1-hydroxybutyl]-3,14-dimethyl-2,5-dioxo-1,4-diazacyclohexadecan-6-yl]isonicotinamide 852878-73-0P, (2R,4S)-4-Hydroxy-2-methyl-N-(3-methylbutyl)-4-((7S,9R)-9-methyl-2,5-dioxo-1,6-diazacyclopentadecan-7-yl)butanamide 852945-05-2P, N-Butyl-4-[(6R)-11-ethyl-15-methoxy-6-methyl-2,12-dioxo-3,11-diazabicyclo[11.3.1]heptadeca-1(17),8,13,15-tetraen-4-yl]-4-hydroxy-2-methylbutyramide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of macrocyclic lactams for treatment of neurol. or vascular disorders related to β-amyloid generation and/or aggregation)
RN 852877-26-0 HCAPLUS
CN 1,4-Diazacyclohexadecane-2,5-dione, 16-[1-hydroxy-2-[[(3-methylphenyl)methyl]amino]ethyl]-3,4,14-trimethyl-, (3S,14R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 852877-37-3 HCAPLUS
CN 1,4-Diazacyclohexadecane-2,5-dione, 16-[1-hydroxy-2-[[(3-methoxyphenyl)methyl]amino]ethyl]-3,4,14-trimethyl-, (3S,14R)- (CA INDEX NAME)

Absolute stereochemistry.

L38 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 852877-38-4 HCAPLUS
CN 1,4-Diazacyclohexadecane-2,5-dione, 16-[1-hydroxy-2-[[2-(4-pyridinyl)ethyl]amino]ethyl]-3,4,14-trimethyl-, (3S,14R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 852877-39-5 HCAPLUS
CN 1,4-Diazacyclohexadecane-2,5-dione, 16-[2-[[2-(3,4-dimethoxyphenyl)ethyl]amino]-1-hydroxyethyl]-3,4,14-trimethyl-, (3S,14R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 852877-40-8 HCAPLUS
CN 1,4-Diazacyclohexadecane-2,5-dione, 16-[1-hydroxy-2-[[(3-methylphenyl)methyl]amino]ethyl]-3,14-dimethyl-, (3S,14R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 852877-41-9 HCAPLUS
CN 1,4-Diazacyclohexadecane-2,5-dione, 16-[1-hydroxy-2-[[(3-methoxyphenyl)methyl]amino]ethyl]-3,14-dimethyl-, (3S,14R)- (CA INDEX NAME)

Absolute stereochemistry.

L38 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 852877-42-0 HCAPLUS
CN 1,4-Diazacyclohexadecane-2,5-dione, 16-[1-hydroxy-2-[[[3-(1-methylethyl)phenyl]methyl]amino]ethyl]-3,14-dimethyl-, (3S,14R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 852877-43-1 HCAPLUS
CN 1,4-Diazacyclohexadecane-2,5-dione, 16-[1-hydroxy-2-[[2-(4-pyridinyl)ethyl]amino]ethyl]-3,14-dimethyl-, (3S,14R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 852877-44-2 HCAPLUS
CN 1,4-Diazacyclohexadecane-2,5-dione, 16-[(1R)-1-hydroxy-2-[[[3-(1-methylethyl)phenyl]methyl]amino]ethyl]-3,4,14-trimethyl-, (3S,14R,16S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 852877-64-6 HCAPLUS
CN 1,4-Diazacyclohexadecane-2,5-dione, 16-[(1R)-2-[[(3-cyclopropylphenyl)methyl]amino]-1-hydroxyethyl]-3,4,14-trimethyl-,

L38 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)
(3S,14R,16S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 852877-65-7 HCAPLUS
CN 1,4-Diazacyclohexadecane-2,5-dione, 16-[(1R)-2-[[(5-bromo-3-pyridinyl)methyl]amino]-1-hydroxyethyl]-3,4,14-trimethyl-, (3S,14R,16S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 852877-66-8 HCAPLUS
CN 1,4-Diazacyclohexadecane-2,5-dione, 16-[(1R)-2-[[(5-cyclopropyl-3-pyridinyl)methyl]amino]-1-hydroxyethyl]-3,4,14-trimethyl-, (3S,14R,16S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 852877-67-9 HCAPLUS
CN 1,4-Diazacyclohexadecane-2,5-dione, 16-[(1R)-2-[[(2-cyclopropyl-4-pyridinyl)methyl]amino]-1-hydroxyethyl]-3,4,14-trimethyl-, (3S,14R,16S)- (CA INDEX NAME)

Absolute stereochemistry.

L38 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 852877-71-5 HCAPLUS
CN 1,4-Diazacycloheptadecane-2,5-dione, 17-[(1R)-1-hydroxy-2-[[[3-(1-methylethyl)phenyl]methyl]amino]ethyl]-3,4,15-trimethyl-, (3S,15R,17S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 852877-73-7 HCAPLUS
CN 1,4-Diazacyclohexadecane-2,5-dione, 16-[(1R)-1-hydroxy-2-[[[3-(1-methylethyl)phenyl]methyl]amino]ethyl]-3,4,8,14-tetramethyl-, (3S,8S,14R,16S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 852877-94-2 HCAPLUS
CN 1,4-Diazacyclopentadecane-5-butanamide, N-butyl-γ-hydroxy-α,2,7-trimethyl-3,15-dioxo-, (αR,γS,2S,5S,7R)- (CA INDEX NAME)

Absolute stereochemistry.



L38 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 852877-68-0 HCAPLUS
CN 1,4-Diazacyclohexadecane-2,5-dione, 16-[(1R)-2-[[3,4-dihydro-2,2-dimethyl-6-(1-methylethyl)-2H-1-benzopyran-4-yl]amino]-1-hydroxyethyl]-3,4,14-trimethyl-, (3S,14R,16S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 852877-69-1 HCAPLUS
CN 1,4-Diazacyclohexadecane-2,5-dione, 16-[(1R)-2-[[[3-(1,1-dimethylethyl)phenyl]methyl]amino]-1-hydroxyethyl]-3,4,14-trimethyl-, (3S,14R,16S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 852877-70-4 HCAPLUS
CN 1,4-Diazacyclohexadecane-2,5-dione, 16-[(1R)-2-[[[3-(2,2-dimethylpropyl)phenyl]methyl]amino]-1-hydroxyethyl]-3,4,14-trimethyl-, (3S,14R,16S)- (CA INDEX NAME)

Absolute stereochemistry.

L38 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)

RN 852877-95-3 HCAPLUS
CN 1,4-Diazacyclohexadecane-5-butanamide, N-butyl-γ-hydroxy-α,2,7-trimethyl-3,16-dioxo-, (αR,γS,2S,5S,7R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 852877-96-4 HCAPLUS
CN 1,4-Diazacycloheptadecane-5-butanamide, N-butyl-γ-hydroxy-α,2,7-trimethyl-3,6-dioxo-, (αR,γS,2S,5S,7R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 852877-97-5 HCAPLUS
CN Carbamic acid, [(3S,6S,12R,14S)-14-[(1S,3R)-4-(butylamino)-1-hydroxy-3-methyl-4-oxobutyl]-3,12-dimethyl-2,5-dioxo-1,4-diazacyclotetradec-6-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 852877-98-6 HCAPLUS
CN 1,4-Diazacyclotetradecane-5-butanamide, N-butyl-γ-hydroxy-α,2,7-trimethyl-3,14-dioxo-, (αR,γS,2S,5S,7R)- (CA INDEX NAME)

L38 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)
Absolute stereochemistry.



RN 852878-03-6 HCAPLUS
CN 1,4-Diazacyclopentadecane-5-butanamide, N-butyl-γ-hydroxy-α,1,2,7-tetramethyl-3,15-dioxo-, (αR,γS,2S,5S,7R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 852878-04-7 HCAPLUS
CN 1,4-Diazacyclohexadecane-5-butanamide, N-butyl-γ-hydroxy-α,1,2,7-tetramethyl-3,16-dioxo-, (αR,γS,2S,5S,7R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 852878-05-8 HCAPLUS
CN 1,4-Diazacycloheptadecane-5-butanamide, N-butyl-γ-hydroxy-α,1,2,7-tetramethyl-3,17-dioxo-, (αR,γS,2S,5S,7R)- (CA INDEX NAME)

Absolute stereochemistry.



L38 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 852878-26-3 HCAPLUS
CN 1,4-Diazacyclopentadecane-5-butanamide, N-butyl-γ-hydroxy-α,2,7,12-tetramethyl-3,15-dioxo-, (αR,γS,2S,5S,7R,12S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 852878-27-4 HCAPLUS
CN 1,4-Diazacyclohexadecane-5-butanamide, 15-(acetylamino)-N-butyl-γ-hydroxy-α,2,7-trimethyl-3,16-dioxo-, (αR,γS,2S,5S,7R,15S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 852878-28-5 HCAPLUS
CN 1,4-Diazacyclohexadecane-5-butanamide, N-butyl-γ-hydroxy-α,2,7-trimethyl-3,16-dioxo-15-[(4-pyridinylcarbonyl)amino]-, (αR,γS,2S,5S,7R,15S)- (CA INDEX NAME)

Absolute stereochemistry.

L38 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)
RN 852878-08-1 HCAPLUS
CN 1,4-Diazacyclohexadecane-5-butanamide, N-butyl-γ-hydroxy-α,1,2,7,13-pentamethyl-3,16-dioxo-, (αR,γS,2S,5S,7R,13S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 852878-09-2 HCAPLUS
CN 1,4-Diazacyclohexadecane-5-butanamide, N-butyl-γ-hydroxy-α,1,2,7,13-pentamethyl-3,16-dioxo-, (αR,γS,2S,5S,7R,13R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 852878-10-5 HCAPLUS
CN 1,4-Diazacyclohexadecane-5-butanamide, N-butyl-γ-hydroxy-α,1,2,7,14-pentamethyl-3,16-dioxo-, (αR,γS,2S,5S,7R,14R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 852878-25-2 HCAPLUS
CN 1,4-Diazacyclopentadecane-5-butanamide, N-butyl-γ-hydroxy-α,2,7,12-tetramethyl-3,15-dioxo-, (αR,γS,2S,5S,7R,12R)- (CA INDEX NAME)

Absolute stereochemistry.

L38 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 852878-73-0 HCAPLUS
CN 1,6-Diazacyclopentadecane-7-butanamide, γ-hydroxy-α,9-dimethyl-N-(3-methylbutyl)-2,5-dioxo-, (αR,γS,7S,9R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 852945-05-2 HCAPLUS
CN 3,11-Diazabicyclo[11.3.1]heptadeca-1(17),8,13,15-tetraene-4-butanamide, N-butyl-11-ethyl-γ-hydroxy-15-methoxy-α,6-dimethyl-2,12-dioxo-, (6R)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



IT 852877-83-9P, [(3S,6S,14R,16S)-16-[(1S,3R)-3-(Butylcarbamoyl)-1-hydroxybutyl]-3,14-dimethyl-2,5-dioxo-1,4-diazacyclohexadecan-6-yl]carbamic acid tert-butyl ester
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(reactant; preparation of macrocyclic lactams for treatment of neurol. or vascular disorders related to β-amyloid generation and/or aggregation)
RN 852877-83-9 HCAPLUS
CN Carbamic acid, [(3S,6S,14R,16S)-16-[(1S,3R)-4-(butylamino)-1-hydroxy-3-methyl-4-oxobutyl]-3,14-dimethyl-2,5-dioxo-1,4-diazacyclohexadec-6-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L38 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)



IT 852877-45-3, (3S,14R,16S)-16-((S)-2-Chloro-1-hydroxyethyl)-3,4,14-trimethyl-1,4-diazacyclohexadecane-2,5-dione
RL: RCT (Reactant); RACT (Reactant or reagent)
(reactant; preparation of macrocyclic lactams for treatment of neurol. or vascular disorders related to β-amyloid generation and/or aggregation)

RN 852877-45-3 HCAPLUS

CN 1,4-Diazacyclohexadecane-2,5-dione, 16-[(1S)-2-chloro-1-hydroxyethyl]-3,4,14-trimethyl-, (3S,14R,16S)- (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d bib abs hitstr l30 tot

L30 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2008 ACS on STN
AN 1998:156138 HCAPLUS
DN 128:230673
OREF 128:45695a,45698a
TI Synthesis of novel cyclic protease inhibitors using Grubbs olefin metathesis
AU Ripka, Amy S.; Bohacek, Regine S.; Rich, Daniel H.
CS School of Pharmacy and Dep. of Chemistry, University of Wisconsin-Madison, Madison, WI, 53706, USA
SO Bioorganic & Medicinal Chemistry Letters (1998), 8(4), 357-360
CODEN: BMCLE8; ISSN: 0960-894X
PB Elsevier Science Ltd.
DT Journal
LA English
OS CASREACT 128:230673
AB The usual amino acid bishomoallylglycine was synthesized and used to form cyclic P3-P1 tripeptide inhibitors via a Grubbs olefin metathesis method. These compds. show micro- to nanomolar inhibition of Rhizopus chinensis pepsin and represent a new class of simplified aspartic protease inhibitors lacking P' residues.
IT 204711-91-1P 204711-92-2P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(synthesis of novel cyclic protease inhibitors using Grubbs olefin metathesis)
RN 204711-91-1 HCAPLUS
CN Carbamic acid, [15-(hydroxymethyl)-3-(1-methylethyl)-2,5-dioxo-1,4-diazacyclopentadec-6-yl]-, 1,1-dimethylethyl ester, [3S-(3R*,6R*,15R*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 204711-92-2 HCAPLUS
CN Carbamic acid, [15-(hydroxymethyl)-3-(1-methylethyl)-2,5-dioxo-1,4-diazacyclopentadec-10-en-6-yl]-, 1,1-dimethylethyl ester, [3S-(3R*,6R*,15R*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RE.CNT 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

```
=> b uspatall
FILE 'USPATFULL' ENTERED AT 11:22:35 ON 23 SEP 2008
CA INDEXING COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATOLD' ENTERED AT 11:22:35 ON 23 SEP 2008
CA INDEXING COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 11:22:35 ON 23 SEP 2008
CA INDEXING COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

=> d bib abs hitrn fhitstr l33 tot
```

L33 ANSWER 1 OF 1 USPATFULL on STN
AN 2007:83324 USPATFULL
TI Macrocyclic lactams and pharmaceutical use thereof
IN Auberson, Yves, Allschwil, SWITZERLAND
Betschart, Claudia, Basel, SWITZERLAND
Glatthar, Ralf, Bad Sackingen, GERMANY, FEDERAL REPUBLIC OF
Laumen, Kurt, March, GERMANY, FEDERAL REPUBLIC OF
Machauer, Rainer, Freiburg, GERMANY, FEDERAL REPUBLIC OF
Tintelnot-Blomley, Marina, Maulburg, GERMANY, FEDERAL REPUBLIC OF
Troxler, Thomas J., Wahlen, SWITZERLAND
Veenstra, Siem Jacob, Lorrach, GERMANY, FEDERAL REPUBLIC OF
PI US-2007007279 2 A1 20070329
AI 2004US-000577260 A1 20041104 (10)
2004WO-EP0012497 20041104
20060602 PCT 371 date
PRAI 2003GB-000025830 20031105
DT Utility
FS APPLICATION
LREP NOVARTIS, CORPORATE INTELLECTUAL PROPERTY, ONE HEALTH PLAZA 104/3, EAST HANOVER, NJ, 07936-1080, US
CLMN Number of Claims: 9
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 2943
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to novel macrocyclic compounds of the formula ##STR1## wherein R.sub.1, R.sub.2, R.sub.3, U, V, W, X, Y, Z and n are as defined in the specification, the number of ring atoms included in the macrocyclic ring being 14, 15, 16 or 17, in free base form or in acid addition salt form, to their preparation, to their use as pharmaceuticals and to pharmaceutical compositions comprising them.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 852877-28-2P, (3S,14R)-16-(2-Chloro-1-hydroxyethyl)-3,4,14-trimethyl-1,4-diazacyclohexadecane-2,5-dione 852877-29-3P, (E)-(3S,14R)-16-(2-Chloro-1-hydroxyethyl)-3,4,14-trimethyl-1,4-diazacyclohexadec-10-ene-2,5-dione 852877-84-0P, [(3S,6S,14R,16S)-16-[(1S,3R)-3-(Butylcarbamoyl)-1-hydroxybutyl]-3,14-dimethyl-2,5-dioxo-1,4-diazacyclohexadec-10-en-6-yl]carbamic acid tert-butyl ester
(intermediate; preparation of macrocyclic lactams for treatment of neurol. or vascular disorders related to β-amyloid generation and/or aggregation)
IT 852877-26-0P, (3S,14R)-16-[1-Hydroxy-2-(3-methylbenzylamino)ethyl]-3,4,14-trimethyl-1,4-diazacyclohexadecane-2,5-dione 852877-37-3P, (3S,14R)-16-[1-Hydroxy-2-(3-methoxybenzylamino)ethyl]-3,4,14-trimethyl-1,4-diazacyclohexadecane-2,5-dione 852877-38-4P, (3S,14R)-16-[1-Hydroxy-2-[[2-(pyridin-4-yl)ethyl]amino]ethyl]-3,4,14-trimethyl-1,4-diazacyclohexadecane-2,5-dione 852877-39-5P, (3S,14R)-16-[2-[[2-(3,4-Dimethoxyphenyl)ethyl]amino]-1-hydroxyethyl]-3,4,14-trimethyl-1,4-diazacyclohexadecane-2,5-dione 852877-40-8P, (3S,14R)-16-[1-Hydroxy-2-(3-methylbenzylamino)ethyl]-3,14-dimethyl-1,4-diazacyclohexadecane-2,5-dione 852877-41-9P, (3S,14R)-16-[1-Hydroxy-2-(3-methoxybenzylamino)ethyl]-3,14-dimethyl-1,4-diazacyclohexadecane-2,5-dione 852877-42-0P, (3S,14R)-16-[1-Hydroxy-2-(3-isopropylbenzylamino)ethyl]-3,14-dimethyl-1,4-diazacyclohexadecane-2,5-dione 852877-43-1P, (3S,14R)-16-[1-Hydroxy-2-[[2-(pyridin-4-yl)ethyl]amino]ethyl]-3,14-dimethyl-1,4-diazacyclohexadecane-2,5-dione 852877-44-2P, (3S,14R,16S)-16-[(1R)-1-Hydroxy-2-(3-isopropylbenzylamino)ethyl]-3,4,14-trimethyl-1,4-diazacyclohexadecane-2,5-dione 852877-64-6P, (3S,14R,16S)-16-[(1R)-2-(3-Cyclopropylbenzylamino)-1-hydroxyethyl]-3,4,14-trimethyl-1,4-diazacyclohexadecane-2,5-dione 852877-65-7P, (3S,14R,16S)-16-[(1R)-2-[(5-Bromopyridin-3-ylmethyl)amino]-1-hydroxyethyl]-3,4,14-trimethyl-1,4-diazacyclohexadecane-2,5-dione 852877-66-8P, (3S,14R,16S)-16-[(1R)-2-[(5-Cyclopropylpyridin-3-ylmethyl)amino]-1-hydroxyethyl]-3,4,14-trimethyl-1,4-diazacyclohexadecane-2,5-dione 852877-67-9P, (3S,14R,16S)-16-[(1R)-2-[(2-Cyclopropylpyridin-4-ylmethyl)amino]-1-hydroxyethyl]-3,4,14-trimethyl-1,4-diazacyclohexadecane-2,5-dione 852877-68-0P, (3S,14R,16S)-16-[(1R)-2-(2,2-Dimethyl-6-isopropylchroman-4-ylamino)-1-

L33 ANSWER 1 OF 1 USPATFULL on STN (Continued)



L33 ANSWER 1 OF 1 USPATFULL on STN (Continued)
hydroxyethyl]-3,4,14-trimethyl-1,4-diazacyclohexadecane-2,5-dione 852877-69-1P, (3S,14R,16S)-16-[(1R)-2-(3-tert-Butylbenzylamino)-1-hydroxyethyl]-3,4,14-trimethyl-1,4-diazacyclohexadecane-2,5-dione 852877-70-4P, (3S,14R,16S)-16-[(1R)-2-[[3-(2,2-Dimethylpropyl)benzyl]amino]-1-hydroxyethyl]-3,4,14-trimethyl-1,4-diazacyclohexadecane-2,5-dione 852877-71-5P, (3S,15R,17S)-17-[(1R)-1-Hydroxy-2-[(3-isopropylbenzyl)amino]ethyl]-3,4,15-trimethyl-1,4-diazacycloheptadecane-2,5-dione 852877-73-7P, (3S,8S,14R,16S)-16-[(1R)-1-Hydroxy-2-(3-isopropylbenzylamino)ethyl]-3,4,8,14-tetramethyl-1,4-diazacyclohexadecane-2,5-dione 852877-94-2P, (2R,4S)-N-Butyl-4-((2S,5S,7R)-2,7-dimethyl-3,15-dioxo-1,4-diazacyclopentadecan-5-yl)-4-hydroxy-2-methylbutanamide 852877-95-3P, (2R,4S)-N-Butyl-4-((2S,5S,7R)-2,7-dimethyl-3,16-dioxo-1,4-diazacyclohexadecan-5-yl)-4-hydroxy-2-methylbutanamide 852877-97-5P, [(3S,6S,12R,14S)-14-[(1S,3R)-3-(Butylcarbamoyl)-1-hydroxybutyl]-3,12-dimethyl-2,5-dioxo-1,4-diazacyclotetradecan-6-yl]carbamic acid tert-butyl ester 852877-98-6P, (2R,4S)-N-Butyl-4-((2S,5S,7R)-2,7-dimethyl-3,14-dioxo-1,4-diazacyclotetradecan-5-yl)-4-hydroxy-2-methylbutanamide 852878-03-6P, (2R,4S)-N-Butyl-4-hydroxy-2-methyl-4-((2S,5S,7R)-1,2,7-trimethyl-3,15-dioxo-1,4-diazacyclopentadecan-5-yl)butanamide 852878-04-7P, (2R,4S)-N-Butyl-4-hydroxy-2-methyl-4-((2S,5S,7R)-1,2,7-trimethyl-3,16-dioxo-1,4-diazacyclohexadecan-5-yl)butanamide 852878-05-8P, (2R,4S)-N-Butyl-4-hydroxy-2-methyl-4-((2S,5S,7R)-1,2,7-trimethyl-3,17-dioxo-1,4-diazacycloheptadecan-5-yl)butanamide 852878-08-1P, (2R,4S)-N-Butyl-4-hydroxy-2-methyl-4-((2S,5S,7R,13S)-1,2,7,13-tetramethyl-3,16-dioxo-1,4-diazacyclohexadecan-5-yl)butanamide 852878-09-2P, (2R,4S)-N-Butyl-4-hydroxy-2-methyl-4-((2S,5S,7R,13R)-1,2,7,13-tetramethyl-3,16-dioxo-1,4-diazacyclohexadecan-5-yl)butanamide 852878-10-5P, (2R,4S)-N-Butyl-4-hydroxy-2-methyl-4-((2S,5S,7R,14R)-1,2,7,14-tetramethyl-3,16-dioxo-1,4-diazacyclohexadecan-5-yl)butanamide 852878-25-2P, (2R,4S)-N-Butyl-4-hydroxy-2-methyl-4-((2S,5S,7R,12R)-2,7,12-trimethyl-3,15-dioxo-1,4-diazacyclopentadecan-5-yl)butanamide 852878-26-3P, (2R,4S)-N-Butyl-4-hydroxy-2-methyl-4-((2S,5S,7R,12S)-2,7,12-trimethyl-3,15-dioxo-1,4-diazacyclopentadecan-5-yl)butanamide 852878-27-4P 852878-28-5P, N-[(3S,6S,14R,16S)-16-[(1S,3R)-3-(Butylcarbamoyl)-1-hydroxybutyl]-3,14-dimethyl-2,5-dioxo-1,4-diazacyclohexadecan-6-yl]isonicotinamide 852878-73-0P, (2R,4S)-4-Hydroxy-2-methyl-N-(3-methylbutyl)-4-((7S,9R)-9-methyl-2,5-dioxo-1,6-diazacyclopentadecan-7-yl)butanamide 852945-05-2P, N-Butyl-4-[(6R)-11-ethyl-15-methoxy-6-methyl-2,12-dioxo-3,11-diazabicyclo[11.3.1]heptadeca-1(17),8,13,15-tetraen-4-yl]-4-hydroxy-2-methylbutyramide
(prepn. of macrocyclic lactams for treatment of neurol. or vascular disorders related to β-amyloid generation and/or aggregation)
IT 852877-83-9P, [(3S,6S,14R,16S)-16-[(1S,3R)-3-(Butylcarbamoyl)-1-hydroxybutyl]-3,14-dimethyl-2,5-dioxo-1,4-diazacyclohexadecan-6-yl]carbamic acid tert-butyl ester
(reactant; preparation of macrocyclic lactams for treatment of neurol. or vascular disorders related to β-amyloid generation and/or aggregation)
IT 852877-45-3, (3S,14R,16S)-16-((S)-2-Chloro-1-hydroxyethyl)-3,4,14-trimethyl-1,4-diazacyclohexadecane-2,5-dione
(reactant; preparation of macrocyclic lactams for treatment of neurol. or vascular disorders related to β-amyloid generation and/or aggregation)
IT 852877-28-2P, (3S,14R)-16-(2-Chloro-1-hydroxyethyl)-3,4,14-trimethyl-1,4-diazacyclohexadecane-2,5-dione
(intermediate; preparation of macrocyclic lactams for treatment of neurol. or vascular disorders related to β-amyloid generation and/or aggregation)
RN 852877-28-2 USPATFULL
CN 1,4-Diazacyclohexadecane-2,5-dione, 16-(2-chloro-1-hydroxyethyl)-3,4,14-trimethyl-, (3S,14R)- (CA INDEX NAME)

Absolute stereochemistry.

=> d bib abs hitrn fhitstr l35 tot

L35 ANSWER 1 OF 26 USPATFULL on STN
AN 2007:256332 USPATFULL
TI Multifunctional Supramolecular Hydrogels as Biomaterials
IN Xu, Bing, Clear Water Bay, HONG KONG
Yang, Zhimou, Clear Water Bay, HONG KONG
Liang, Gaolin, Clear Water Bay, HONG KONG
Wang, Qigang, Clear Water Bay, HONG KONG
PI US-20070224273 A1 20070927
AI 2007US-000692857 A1 20070328 (11)
RLI Continuation-in-part of Ser. No. 2005US-000237498, filed on 27 Sep 2005, PENDING Continuation-in-part of Ser. No. 2005WO-US035112, filed on 27 Sep 2005, PENDING
PRAI 2004US-000613413P 20040928 (60) <--
2004US-000613413P 20040928 (60) <--
2007US-000878053P 20070103 (60)
DT Utility
FS APPLICATION
LREP LAW OFFICES OF ALBERT WAI-KIT CHAN, LLC, WORLD PLAZA, SUITE 604, 141-07 20TH AVENUE, WHITESTONE, NY, 11357, US
CLMN Number of Claims: 29
ECL Exemplary Claim: 1
DRWN 24 Drawing Page(s)
LN.CNT 1968
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides supramolecular hydrogels having a three-dimensional, self-assembling, elastic, network structure comprising non-polymeric, functional molecules and a liquid medium, whereby the functional molecules are noncovalently crosslinked. The functional molecules may be, for instance, anti-inflammatory molecules, antibiotics, metal chelators, anticancer agents, small peptides, surface-modified nanoparticles, or a combination thereof. Applications of the present invention include use of the supramolecular hydrogel, for instance, as a biomaterial for wound healing, tissue engineering, drug delivery, and drug/inhibitor screening.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 950831-25-1
(multifunctional supramol. hydrogels as biomaterials)
IT 950831-25-1
(multifunctional supramol. hydrogels as biomaterials)
RN 950831-25-1 USPATFULL
CN Vancomycin, 26-decarboxy-26-[(1-pyrenylamino)carbonyl]- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



L35 ANSWER 1 OF 26 USPATFULL on STN (Continued)

PAGE 2-A



L35 ANSWER 2 OF 26 USPATFULL on STN
AN 2007:69257 USPATFULL
TI Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors
IN Nakajima, Suanne, Cambridge, MA, UNITED STATES
Miao, Zhenwei, Medway, MA, UNITED STATES
Sun, Ying, Waltham, MA, UNITED STATES
Tang, Datong, Malden, MA, UNITED STATES
Xu, Guoyou, Auburndale, MA, UNITED STATES
Porter, Brian, Cambridge, MA, UNITED STATES
Or, Yat Sun, Watertown, MA, UNITED STATES
Wang, Zhe, Hockessin, DE, UNITED STATES
PA Enanta Pharmaceuticals, Inc., Watertown, MA, UNITED STATES (U.S. corporation)
PI US-20070060510 A1 20070315
US------7368452 B2 20080506
AI 2006US-000489011 A1 20060718 (11)
RLI Continuation of Ser. No. 2004US-000826743, filed on 16 Apr 2004, PENDING
PRAI 2003US-000509071P 20030418 (60) <--
DT Utility
FS APPLICATION
LREP EDWARDS & ANGELL, LLP, P.O. BOX 55874, BOSTON, MA, 02205, US
CLMN Number of Claims: 5
ECL Exemplary Claim: 1-10
DRWN No Drawings
LN.CNT 3446
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to compounds of Formula I or II, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: ##STR1## which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 787600-38-8P
(preparation of quinoxalinyl cyclic peptides as hepatitis C serine protease inhibitors)
IT 787600-38-8P
(preparation of quinoxalinyl cyclic peptides as hepatitis C serine protease inhibitors)
RN 787600-38-8 USPATFULL
CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[(1,1-dimethylethoxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-2-[[3-(2-thienyl)benzo[g]quinoxalin-2-yl]oxy]-, (2R,6S,13aS,14aR,16aS)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.

PAGE 1-A



L35 ANSWER 2 OF 26 USPATFULL on STN (Continued)

PAGE 1-B



PAGE 2-B

L35 ANSWER 3 OF 26 USPATFULL on STN
AN 2006:254839 USPATFULL
TI Neuroprotective macrocyclic compounds and methods for their use
IN Harris, Paul William Richard, Auckland, NEW ZEALAND
Brimble, Margaret Anne, Auckland, NEW ZEALAND
PA NEUREN PHARMACEUTICALS LTD., Auckland, NEW ZEALAND (non-U.S. corporation)
PI US-20060217295 A1 20060928
AI 2004US-000549951 A1 20040316 (10) <--
2004WO-US008108 20040316 <--
20060301 PCT 371 date
PRAI 2003US-000456136P 20030320 (60) <--
2003US-000505119P 20030923 (60) <--
DT Utility
FS APPLICATION
LREP FLIESLER MEYER, LLP, FOUR EMBARCADERO CENTER, SUITE 400, SAN FRANCISCO, CA, 94111, US
CLMN Number of Claims: 36
ECL Exemplary Claim: 1
DRWN 3 Drawing Page(s)
LN.CNT 2932
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Embodiments of this invention provide novel peptidomimetics that contain a macrocycle. Such compounds are neuroprotective and have utility as therapeutic agents for treatment of diseases, injuries and other conditions characterised by neuronal degeneration and/or death. Compounds are also useful for manufacture of medicaments useful for treatment of such conditions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 765313-65-3P 765313-66-4P 765313-89-1P
765313-90-4P 765313-91-5P 765313-92-6P
765313-93-7P 765313-94-8P 765313-95-9P
765313-96-0P 765313-97-1P
(preparation of neuroprotective macrocyclic compds.)
IT 765313-65-3P
(preparation of neuroprotective macrocyclic compds.)
RN 765313-65-3 USPATFULL
CN 1H-Pyrrolo[1,2-a][1,4]diazacyclotridecine-3,5-dicarboxylic acid, 10-aminotetradecahydro-1,11-dioxo-, (3S,5R,10S,15aS)- (CA INDEX NAME)

Absolute stereochemistry.



L35 ANSWER 4 OF 26 USPATFULL on STN
AN 2005:177796 USPATFULL
TI Macrocyclic hepatitis C serine protease inhibitors
IN Miao, Zhenwei, San Diego, CA, UNITED STATES
Sun, Ying, Waltham, MA, UNITED STATES
Nakajima, Suanne, Cambridge, MA, UNITED STATES
Tang, Datong, Malden, MA, UNITED STATES
Wu, Frank, Shrewsbury, MA, UNITED STATES
Xu, Guoyou, Auburndale, MA, UNITED STATES
Or, Yat S., Watertown, MA, UNITED STATES
Wang, Zhe, Hockessin, DE, UNITED STATES
PI US-20050153877 A1 20050714
AI 2004US-000774047 A1 20040206 (10) <--
PRAI 2003US-000509069P 20030213 (60) <--
DT Utility
FS APPLICATION
LREP EDWARDS & ANGELL, LLP, P.O. BOX 55874, BOSTON, MA, 02205, US
CLMN Number of Claims: 77
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 7932
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to compounds of Formula I, II or III, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: ##STR1## wherein W is a substituted or unsubstituted heterocyclic ring system. The compounds inhibit serine protease activity, particularly the activity of hepatitis c virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis c virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 744249-71-6P 858950-33-1P
(synthesis of macrocyclic hepatitis C virus (HCV) serine protease NS3 inhibitors)
IT 744249-71-6P
(synthesis of macrocyclic hepatitis C virus (HCV) serine protease NS3 inhibitors)
RN 744249-71-6 USPATFULL
CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[(1,1-dimethylethoxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-(9-methoxy-4-oxopyridazino[4,5-c]isoquinolin-3(4H)-yl)-5,16-dioxo-, (2R,6S,13aS,14aR,16aS)- (CA INDEX NAME)



L35 ANSWER 5 OF 26 USPATFULL on STN
AN 2005:138518 USPATFULL
TI Macrocyclic inhibitors of hepatitis C virus NS3-serine protease
IN Venkatraman, Srikanth, Woodbridge, NJ, UNITED STATES
Njoroge, F. George, Warren, NJ, UNITED STATES
Wu, Wanli, Edison, NJ, UNITED STATES
Girijavallabhan, Viyyoor M., Parsippany, NJ, UNITED STATES
McKittrick, Brian, New Vernon, NJ, UNITED STATES
Su, Jing, Scotch Plains, NJ, UNITED STATES
Velazquez, Francisco, Clinton, NJ, UNITED STATES
Pinto, Patrick A., Morris Plains, NJ, UNITED STATES
PA SCHERING CORPORATION (U.S. corporation)
PI US-20050119168 A1 20050602
AI 2004US-000948367 A1 20040923 (10) <--
PRAI 2003US-000506637P 20030926 (60) <--
DT Utility
FS APPLICATION
LREP SCHERING-PLOUGH CORPORATION, PATENT DEPARTMENT (K-6-1, 1990), 2000 GALLOPING HILL ROAD, KENILWORTH, NJ, 07033-0530, US
CLMN Number of Claims: 55
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 5428
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention discloses novel compounds which have HCV protease inhibitory activity as well as pharmaceutical compositions comprising such compounds and methods of using them to treat disorders associated with the HCV protease. The novel compounds typically include a 15-20 member macrocycle and have the general structure of structural Formula 1: ##STR1## wherein Z', L', M', R.sub.1, X and D are defined herein.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 848775-50-8P
(macrocyclic inhibitors of hepatitis C virus NS3 serine protease and their use in treating disorders associated with HCV protease)
IT 848776-70-5P 848776-71-6P 848776-72-7P
(macrocyclic inhibitors of hepatitis C virus NS3 serine protease and their use in treating disorders associated with HCV protease)
IT 848775-50-8P
(macrocyclic inhibitors of hepatitis C virus NS3 serine protease and their use in treating disorders associated with HCV protease)
RN 848775-50-8 USPATFULL
CN Glycine, L-prolyl-(3S,11S)-3-amino-11-carboxy-11-[[(2-methylpropoxy)carbonyl]amino]-2-oxoundecanoylglycyl-2-phenyl-, 4-(1,1-dimethylethyl) ester, (2→1)-lactam, (2S)- (9CI) (CA INDEX NAME)



L35 ANSWER 6 OF 26 USPATFULL on STN
AN 2005:88018 USPATFULL
TI Glycopeptide antibiotics, combinatorial libraries of glycopeptide antibiotics and methods of producing same
IN Kahne, Daniel, Princeton, NJ, UNITED STATES
Kerns, Robert, Troy, MI, UNITED STATES
Fukuzawa, Seketsu, Tokyo, JAPAN
Ge, Min, Princeton, NJ, UNITED STATES
Thompson, Christopher, Milford, MA, UNITED STATES
PA Trustees of Princeton University (U.S. corporation)
PI US-20050075483 A1 20050407
US-----7331920 B2 20080219
AI 2003US-000676391 A1 20031001 (10) <--
RLI Division of Ser. No. 1999US-000353368, filed on 14 Jul 1999, GRANTED, Pat. No. US-----6710168
PRAI 1999US-000134839P 19990519 (60) <--
DT Utility
FS APPLICATION
LREP WOODCOCK WASHBURN LLP, ONE LIBERTY PLACE, 46TH FLOOR, 1650 MARKET STREET, PHILADELPHIA, PA, 19103
CLMN Number of Claims: 116
ECL Exemplary Claim: 1
DRWN 26 Drawing Page(s)
LN.CNT 4349
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A glycopeptide of the formula A.sub.1-A.sub.2-A.sub.3-A.sub.4-A.sub.5-A.sub.6-A.sub.7, in which each dash represents a covalent bond; wherein A.sub.1 comprises a modified or unmodified α-amino acid residue, alkyl, aryl, aralkyl, alkanoyl, aroyl, aralkanoyl, heterocyclic, heterocyclic-carbonyl, heterocyclic-alkyl, heterocyclic-alkyl-carbonyl, alkylsulfonyl, arylsulfonyl, guanidinyl, carbamoyl, or xanthyl; wherein each of A.sub.2 to A.sub.7 comprises a modified or unmodified α-amino acid residue, whereby (i) A.sub.1 is linked to an amino group on A.sub.2, (ii) each of A.sub.2, A.sub.4 and A.sub.6 bears an aromatic side chain, which aromatic side chains are cross-linked together by two or more covalent bonds, and (iii) A.sub.7 bears a terminal carboxyl, ester, amide, or N-substituted amide group;

and wherein one or more of A.sub.1 to A.sub.7 is linked via a glycosidic bond to one or more glycosidic groups each having one or more sugar residues, at least one of the sugar residues bearing one or more substituents of the formula YXR, N.sup.+(R.sub.1).dbd.CR.sub.2R.sub.3, N.dbd.PR.sub.1R.sub.2R.sub.3, N.sup.+R.sub.1R.sub.2R.sub.3 or P.sup.+R.sub.1R.sub.2R.sub.3 in which Y is a single bond, O, NR.sub.1 or S; X is O, NR.sub.1, S, SO.sub.2, C(O)O, C(O)S, C(S)O, C(S)S, C(NR.sub.1)O, C(O)NR.sub.1, or halo (in which case Y and R are absent).

A chemical library comprising a plurality of the glycopeptides of the invention.

A method for preparing a glycopeptide by glycosylation of an aglycone derived from a glycopeptide antibiotic.

A method for preparing a glycopeptide by preparing a pseudoaglycone from a glycopeptide antibiotic and glycosylating the pseudoaglycone.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 256350-24-0P
(preparation of glycopeptide antibiotics and their combinatorial libraries)
IT 256350-24-0P
(preparation of glycopeptide antibiotics and their combinatorial libraries)
RN 256350-24-0 USPATFULL
CN Vancomycin, 6'-deoxy-6'-[(2-pyrenylsulfonyl)oxy]-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 256350-23-9
CMF C82 H83 Cl2 N9 O26 S

Absolute stereochemistry.

L35 ANSWER 6 OF 26 USPATFULL on STN (Continued)

PAGE 1-A



PAGE 1-B



L35 ANSWER 6 OF 26 USPATFULL on STN (Continued)

PAGE 2-A



PAGE 2-B



PAGE 3-B

CM 2

CRN 76-05-1
CMF C2 H F3 O2

L35 ANSWER 7 OF 26 USPATFULL on STN

AN 2005:36989 USPATFULL
TI Porous body with antibiotic coating, method for production, and use
IN Vogt, Sebastian, Erfurt, GERMANY, FEDERAL REPUBLIC OF
Schnabelrauch, Matthias, Jena, GERMANY, FEDERAL REPUBLIC OF
Kuhn, Klaus-Dieter, Marburg, GERMANY, FEDERAL REPUBLIC OF
PA Heraeus Kulzer GmbH & Co. KG, Hanau, GERMANY, FEDERAL REPUBLIC OF (non-U.S. corporation)
PI US-20050031664 A1 20050210
AI 2004US-000831680 A1 20040423 (10) <--
PRAI 2003DE-010318991 20030425 <--
DT Utility
FS APPLICATION
LREP NORRIS, MCLAUGHLIN & MARCUS, PA, 875 THIRD STREET, 18TH FLOOR, NEW YORK, NY, 10022
CLMN Number of Claims: 16
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 477
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The production and use of a porous body with an antibiotic coating is described. A coating composed of at least one antibiotic salt, sparingly soluble in water or in an aqueous environment, from the group comprising fusidic acid-antibiotics, for example, fusidic acid-gentamicin, fusidic acid-sisomicin, fusidic acid-netilmicin, fusidic acid-streptomycin, fusidic acid-tobramycin, fusidic acid-spectinomycin, fusidic acid-vancomycin, fusidic acid-ciprofloxacin, fusidic acid-moxifloxacin, fusidic acid-clindamycin, fusidic acid-lincomycin, fusidic acid-tetracycline, fusidic acid-chlorotetracycline, fusidic acid-oxytetracycline, and fusidic acid-rolitetracycline is introduced into the pore system of nonmetallic porous bodies and metallic porous bodies. The antibiotically coated porous bodies are used as implants.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 780771-93-9
(porous carriers coated with fusidinic acid salts of antibiotics for use as implants and method for preparation)
IT 780771-93-9
(porous carriers coated with fusidinic acid salts of antibiotics for use as implants and method for preparation)
RN 780771-93-9 USPATFULL
CN 29-Nordammara-17(20),24-dien-21-oic acid, 16-(acetyloxy)-3,11-dihydroxy-, (3α,4α,8α,9β,11α,13α,14β,16.beta
.,17Z)-, compd. with vancomycin (9CI) (CA INDEX NAME)

CM 1

CRN 6990-06-3
CMF C31 H48 O6
CDES 4:3A,4A,8A,9B,11A,13A,14B,16B,17Z.DAMMARANE

Absolute stereochemistry.
Double bond geometry as shown.



CM 2

CRN 1404-90-6
CMF C66 H75 C12 N9 O24

L35 ANSWER 7 OF 26 USPATFULL on STN (Continued)
Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

PAGE 2-A



L35 ANSWER 8 OF 26 USPATFULL on STN
AN 2004:335576 USPATFULL
TI Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors
IN Nakajima, Suanne, Cambridge, MA, UNITED STATES
Zhenwei, Miao, Medway, MA, UNITED STATES
Sun, Ying, Waltham, MA, UNITED STATES
Tang, Datong, Malden, MA, UNITED STATES
Xu, Guoyou, Auburndale, MA, UNITED STATES
Porter, Brian, Cambridge, MA, UNITED STATES
Or, Yat Sun, Watertown, MA, UNITED STATES
Wang, Zhe, Hockessin, GERMANY, FEDERAL REPUBLIC OF
PI US-2004266668 A1 20041230
US-----7176208 B2 20070213
AI 2004US-000826743 A1 20040416 (10) <--
PRAI 2003US-000509071P 20030418 (60) <--
DT Utility
FS APPLICATION
LREP EDWARDS & ANGELL, LLP, P.O. BOX 55874, BOSTON, MA, 02205
CLMN Number of Claims: 14
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 3936
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to compounds of Formula I or II, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: ##STR1##

which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 787600-38-8P
(preparation of quinoxalinyl cyclic peptides as hepatitis C serine protease inhibitors)
IT 787600-38-8P
(preparation of quinoxalinyl cyclic peptides as hepatitis C serine protease inhibitors)
RN 787600-38-8 USPATFULL
CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[(1,1-dimethylethoxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-2-[[3-(2-thienyl)benzo[g]quinoxalin-2-yl]oxy]-, (2R,6S,13aS,14aR,16aS)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.

PAGE 1-A



L35 ANSWER 8 OF 26 USPATFULL on STN (Continued)

PAGE 1-B



PAGE 2-B

L35 ANSWER 9 OF 26 USPATFULL on STN
AN 2004:267777 USPATFULL
TI Reagents and methods for the detection and quantification of vancomycin in bilogical fluids
IN Adamczyk, Maciej, Gurnee, IL, UNITED STATES
Brate, Elaine M., Grayslake, IL, UNITED STATES
Perkowitz, Mary M., Lake Zurich, IL, UNITED STATES
Rege, Sushil D., Gurnee, IL, UNITED STATES
PI US-2004209318 A1 20041021 <--
AI 2004US-000845383 A1 20040513 (10) <--
RLI Division of Ser. No. 1998US-000026869, filed on 20 Feb 1998, ABANDONED Continuation of Ser. No. 1995US-000416567, filed on 4 Apr 1995, ABANDONED
DT Utility
FS APPLICATION
LREP STEVEN F. WEINSTOCK, ABBOTT LABORATORIES, 100 ABBOTT PARK ROAD, DEPT. 377/AP6A, ABBOTT PARK, IL, 60064-6008
CLMN Number of Claims: 38
ECL Exemplary Claim: 1
DRWN 26 Drawing Page(s)
LN.CNT 1611
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Immunoassay reagents, methods and test kits for the specific quantification of vancomycin in a test sample are disclosed. The reagent comprises antibodies prepared with immunogens of FIG. 6 wherein P is an immunogenic carrier material and X is a linking moiety.

Also described is the synthesis of labeled reagents of FIG. 8 wherein Q is a detectable moiety, preferably fluorescein or a fluorescein derivative, and X is a linking moiety.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 183747-02-6P
(immunoassay reagents and methods for the detection and quantification of vancomycin in biol. fluids, and preparation of immunogen, tracer, and monoclonal antibody)
IT 183747-02-6P
(immunoassay reagents and methods for the detection and quantification of vancomycin in biol. fluids, and preparation of immunogen, tracer, and monoclonal antibody)
RN 183747-02-6 USPATFULL
CN Vancomycin, 56-[4-[[3-carboxy-4-(3-oxo-3H-xanthen-9-yl)phenyl]amino]-6-chloro-1,3,5-triazin-2-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-B



L35 ANSWER 9 OF 26 USPATFULL on STN (Continued)

PAGE 2-A



PAGE 2-B



PAGE 3-A



L35 ANSWER 10 OF 26 USPATFULL on STN
AN 2004:233741 USPATFULL
TI Pyridazinonyl macrocyclic hepatitis C serine protease inhibitors
IN Nakajima, Suanne, Cambridge, MA, UNITED STATES
Tang, Datong, Malden, MA, UNITED STATES
Wu, Frank, Shrewsbury, MA, UNITED STATES
Miao, Zhenwei, Medway, MA, UNITED STATES
Sun, Ying, Waltham, MA, UNITED STATES
Or, Yat Sun, Watertown, MA, UNITED STATES
Wang, Zhe, Hockessin, DE, UNITED STATES
PI US-20040180815 A1 20040916 <--
AI 2003US-000384120 A1 20030307 (10) <--
DT Utility
FS APPLICATION
LREP ENANTA PHARMACEUTICALS, INC., ATTN: PATENT DEPT., 500 ARSENAL STREET, WATERTOWN, MA, 02472
CLMN Number of Claims: 16
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 2590
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to compounds of Formula I or II, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: ##STR1##

which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 744249-71-6P
(macrocyclic hepatitis C virus (HCV) serine protease NS3 inhibitors, their synthesis and use to prevent HCV infection)
IT 744249-71-6P
(macrocyclic hepatitis C virus (HCV) serine protease NS3 inhibitors, their synthesis and use to prevent HCV infection)
RN 744249-71-6 USPATFULL
CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[(1,1-dimethylethoxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-(9-methoxy-4-oxopyridazino[4,5-c]isoquinolin-3(4H)-yl)-5,16-dioxo-, (2R,6S,13aS,14aR,16aS)- (CA INDEX NAME)



L35 ANSWER 11 OF 26 USPATFULL on STN
AN 2004:139596 USPATFULL
TI Glycopeptide antibiotics, combinatorial libraries of glycopeptide antibiotics and methods of producing same
IN Kahne, Daniel, Princeton, NJ, UNITED STATES
Kerns, Robert, Troy, MI, UNITED STATES
Fukuzawa, Seketsu, Tokyo, JAPAN
Ge, Min, Princeton, NJ, UNITED STATES
Thompson, Christopher, Milford, MA, UNITED STATES
PI US-20040106772 A1 20040603 <--
AI 2003US-000631883 A1 20030731 (10) <--
RLI Division of Ser. No. 1999US-000353368, filed on 14 Jul 1999, GRANTED, Pat. No. US-6710168
PRAI 1999US-000134839P 19990519 (60) <--
DT Utility
FS APPLICATION
LREP WOODCOCK WASHBURN LLP, ONE LIBERTY PLACE, 46TH FLOOR, 1650 MARKET STREET, PHILADELPHIA, PA, 19103
CLMN Number of Claims: 116
ECL Exemplary Claim: 1
DRWN 26 Drawing Page(s)
LN.CNT 4343
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A glycopeptide of the formula A.sub.1-A.sub.2-A.sub.3-A.sub.4-A.sub.5-A.sub.6-A.sub.7, in which each dash represents a covalent bond; wherein A.sub.1 comprises a modified or unmodified α-amino acid residue, alkyl, aryl, aralkyl, alkanoyl, aroyl, aralkanoyl, heterocyclic, heterocyclic-carbonyl, heterocyclic-alkyl, heterocyclic-alkyl-carbonyl, alkylsulfonyl, arylsulfonyl, guanidinyl, carbamoyl, or xanthyl; wherein each of A.sub.2 to A.sub.7 comprises a modified or unmodified α-amino acid residue, whereby (i) A.sub.1 is linked to an amino group on A.sub.2, (ii) each of A.sub.2, A.sub.4 and A.sub.6 bears an aromatic side chain, which aromatic side chains are cross-linked together by two or more covalent bonds, and (iii) A.sub.7 bears a terminal carboxyl, ester, amide, or N-substituted amide group;

and wherein one or more of A.sub.1 to A.sub.7 is linked via a glycosidic bond to one or more glycosidic groups each having one or more sugar residues, at least one of the sugar residues bearing one or more substituents of the formula YXR, N.sup.+(R.sub.1)=CR.sub.2R.sub.3, N=PR.sub.1R.sub.2R.sub.3, N.sup.+R.sub.1R.sub.2R.sub.3 or P.sup.+R.sub.1R.sub.2R.sub.3 in which Y is a single bond, O, NR, or S; X is O, NR.sub.1, S, SO.sub.2, C(O)O, C(O)S, C(S)O, C(S)S, C(NR.sub.1)O, C(O)NR.sub.1, or halo (in which case Y and R are absent).

A chemical library comprising a plurality of the glycopeptides of the invention.

A method for preparing a glycopeptide by glycosylation of an aglycone derived from a glycopeptide antibiotic.

A method for preparing a glycopeptide by preparing a pseudoaglycone from a glycopeptide antibiotic and glycosylating the pseudoaglycone.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 256350-24-0P
(preparation of glycopeptide antibiotics and their combinatorial libraries)
IT 256350-24-0P
(preparation of glycopeptide antibiotics and their combinatorial libraries)
RN 256350-24-0 USPATFULL
CN Vancomycin, 6'-deoxy-6'-[(2-pyrenylsulfonyl)oxy]-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 256350-23-9
CMF C82 H83 Cl2 N9 O26 S

Absolute stereochemistry.

L35 ANSWER 11 OF 26 USPATFULL on STN (Continued)

PAGE 1-A



PAGE 1-B



PAGE 2-A



L35 ANSWER 11 OF 26 USPATFULL on STN (Continued)

PAGE 2-B



PAGE 3-B

CM 2

CRN 76-05-1
CMF C2 H F3 O2

L35 ANSWER 12 OF 26 USPATFULL on STN

AN 2004:72659 USPATFULL
TI Glycopeptide antibiotics, combinatorial libraries of glycopeptide antibiotics and methods of producing same
IN Kahne, Daniel, Princeton, NJ, United States
Kerns, Robert, Troy, MI, United States
Fukuzawa, Seketsu, Tokyo, JAPAN
Ge, Min, Prineton, NJ, United States
Thompson, Christopher, Milford, MA, United States
PA The Trustees of the University of Princeton, Princeton, NJ, United States (U.S. corporation)
PI US-----6710162 B1 20040323 <--
AI 1999US-000353368 19990714 (9) <--
PRAI 1999US-000134839P 19990519 (60) <--
DT Utility
FS GRANTED
EXNAM Primary Examiner: Celsa, Bennett
LREP Woodcock Washburn LLP
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN 26 Drawing Figure(s); 26 Drawing Page(s)
LN.CNT 4017
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A glycopeptide of the formula A.sub.1--A.sub.2--A.sub.3--A.sub.4--A.sub.5--A.sub.6--A.sub.7, in which each dash represents a covalent bond; wherein A.sub.1 comprises a modified or unmodified α-amino acid residue, alkyl, aryl, aralkyl, alkanoyl, aroyl, aralkanoyl, heterocyclic, heterocyclic-carbonyl, heterocyclic-alkyl, heterocyclic-alkyl-carbonyl, alkylsulfonyl, arylsulfonyl, guanidinyl, carbamoyl, or xanthyl; wherein each of A.sub.2 to A.sub.7 comprises a modified or unmodified α-amino acid residue, whereby (i) A.sub.1 is linked to an amino group on A.sub.2, (ii) each of A.sub.2, A.sub.4 and A.sub.6 bears an aromatic side chain, which aromatic side chains are cross-linked together by two or more covalent bonds, and (iii) A.sub.7 bears a terminal carboxyl, ester, amide, or N-substituted amide group;

and wherein one or more of A.sub.1 to A.sub.7 is linked via a glycosidic bond to one or more glycosidic groups each having one or more sugar residues, at least one of the sugar residues bearing one or more substituents of the formula YXR, N.sup.+(R.sub.1).dbd.CR.sub.2R.sub.3, N.dbd.PR.sub.1R.sub.2R.sub.3, N.sup.+R.sub.1R.sub.2R.sub.3 or P.sup.+R.sub.1R.sub.2R.sub.3 in which Y is a single bond, O, NR.sub.1 or S; X is O, NR.sub.1, S, SO.sub.2, C(O)O, C(O)S, C(S)O, C(S)S, C(NR.sub.1)O, C(O)NR.sub.1, or halo (in which case Y and R are absent).

A chemical library comprising a plurality of the glycopeptides of the invention.

A method for preparing a glycopeptide by glycosylation of an aglycone derived from a glycopeptide antibiotic.

A method for preparing a glycopeptide by preparing a pseudoaglycone from a glycopeptide antibiotic and glycosylating the pseudoaglycone.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 256350-24-0P
(preparation of glycopeptide antibiotics and their combinatorial libraries)
IT 256350-24-0P
(preparation of glycopeptide antibiotics and their combinatorial libraries)
RN 256350-24-0 USPATFULL
CN Vancomycin, 6'-deoxy-6'-[(2-pyrenylsulfonyl)oxy]-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 256350-23-9
CMF C82 H83 Cl2 N9 O26 S

Absolute stereochemistry.

L35 ANSWER 12 OF 26 USPATFULL on STN (Continued)

PAGE 1-A



PAGE 1-B



L35 ANSWER 12 OF 26 USPATFULL on STN (Continued)

PAGE 2-A



PAGE 2-B



PAGE 3-B

CM 2

CRN 76-05-1
CMF C2 H F3 O2

L35 ANSWER 13 OF 26 USPATFULL on STN

AN 2004:51441 USPATFULL
TI Inhibitors of hepatitis C virus
IN Campbell, Jeffrey Allen, Cheshire, CT, UNITED STATES
Good, Andrew Charles, Wallingford, CT, UNITED STATES
PI US-20040038872 A1 20040226 <--
US-----6867185 B2 20050315
AI 2002US-000317451 A1 20021212 (10) <--
PRAI 2002US-000382103P 20020520 (60) <--
2001US-000344080P 20011220 (60) <--
DT Utility
FS APPLICATION
LREP STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000
CLMN Number of Claims: 14
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 5050
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to macrocyclic compounds, methods for making these compounds, pharmaceutical compositions and the therapeutic or prophylactic use of these compounds by administering said compounds to mammals to prevent or treat hepatitis C virus (HCV) infection.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 552334-90-4P 552334-92-6P
(preparation of macrocyclic compds. as inhibitors of hepatitis C virus)
IT 552334-91-5P 552334-93-7P
(preparation of macrocyclic compds. as inhibitors of hepatitis C virus)
IT 552335-27-0P 552335-30-5P
(preparation of macrocyclic compds. as inhibitors of hepatitis C virus)
IT 552334-90-4P
(preparation of macrocyclic compds. as inhibitors of hepatitis C virus)
RN 552334-90-4 USPATFULL
CN Carbamic acid, [(2R,6S,9E,10aS,11aR,13aS)-11a-[[(cyclopropylsulfonyl)amino]carbonyl]-2,3,5,6,7,8,10a,11,11a,12,13,13a-dodecahydro-2-[(7-methoxy-2-phenyl-4-quinolinyl)oxy]-5,13-dioxo-1H-cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclododecin-6-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



L35 ANSWER 14 OF 26 USPATFULL on STN
AN 2004:2425 USPATFULL
TI Macrocyclic peptides active against the hepatitis C virus
IN Tsantrizos, Youla S., Saint-Laurent, CANADA
Cameron, Dale R., Rosemere, CANADA
Faucher, Anne-Marie, Oka, CANADA
Ghiro, Elise, Laval, CANADA
Goudreau, Nathalie, Mont-Royal, CANADA
Halmos, Teddy, Laval, CANADA
Llinas-Brunet, Montse, Dollard-des-Ormeaux, CANADA
PA Boehringer Ingelheim (Canada) Ltd., Laval, CANADA (non-U.S. corporation)
PI US-2004002448 A1 20040101 <--
AI 2003US-000358726 A1 20030205 (10) <--
RLI Continuation of Ser. No. 2001US-000760946, filed on 16 Jan 2001, PENDING
Continuation-in-part of Ser. No. 2000US-000542675, filed on 3 Apr 2000, ABANDONED
PRAI 1999US-000128011P 19990406 (60) <--
DT Utility
FS APPLICATION
LREP BOEHRINGER INGELHEIM CORPORATION, 900 RIDGEBURY RD, P O BOX 368, RIDGEFIELD, CT, 06877
CLMN Number of Claims: 1
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 3518
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention covers macrocyclic compounds of formula I active in-vitro and in cellular assays against the NS3 protease of the hepatitis C virus. ##STR1##

wherein W, R.sup.21, R.sup.22, R.sup.3, R.sup.4, D and A are as defined herein, or a pharmaceutically acceptable salt or ester thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 300831-95-2P 300831-99-6P
(preparation of macrocyclic peptides active against the hepatitis C virus)
IT 300831-95-2P
(preparation of macrocyclic peptides active against the hepatitis C virus)
RN 300831-95-2 USPATFULL
CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclotridecine-12a(5H)-carboxylic acid, 6-[[(1,1-dimethylethoxy)carbonyl]amino]-1,2,3,6,7,8,9,11a,12,13,14,14a-dodecahydro-2-[(7-methoxy-2-phenyl-4-quinolinyl)oxy]-5,14-dioxo-, (2R,6S,10E,11aR,12aR,14aS)- (CA INDEX NAME)

STRUCTURE DIAGRAM IS NOT AVAILABLE

L35 ANSWER 15 OF 26 USPATFULL on STN
AN 2003:222086 USPATFULL
TI Macrocyclic peptides active against the hepatitis C virus
IN Tsantrizos, Youla S., Saint-Laurent, CANADA
Cameron, Dale R., Rosemere, CANADA
Faucher, Anne-Marie, Oka, CANADA
Ghiro, Elise, Laval, CANADA
Goudreau, Nathalie, Mont-Royal, CANADA
Halmos, Teddy, Laval, CANADA
Llinas-Brunet, Montse, Dollard-des-Ormeaux, CANADA
PA Boehringer Ingelheim (Canada) Ltd, Laval, CANADA (non-U.S. corporation)
PI US-----6608027 B1 20030819 <--
AI 2001US-000760946 20010116 (9) <--
RLI Continuation-in-part of Ser. No. 2000US-000542675, filed on 3 Apr 2000, now abandoned
PRAI 1999US-000128011P 19990406 (60) <--
DT Utility
FS GRANTED
EXNAM Primary Examiner: Russel, Jeffrey E.
LREP Raymond, Robert P., Datlow, Philip I., Stempel, Alan R.
CLMN Number of Claims: 145
ECL Exemplary Claim: 1
DRWN 0 Drawing Figure(s); 0 Drawing Page(s)
LN.CNT 3940
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention covers macrocyclic compounds of formula I active in-vitro and in cellular assays against the NS3 protease of the hepatitis C virus. ##STR1##

wherein W, R.sup.21, R.sup.22, R.sup.3, R.sup.4, D and A are as defined herein, or a pharmaceutically acceptable salts or ester thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 300831-95-2P 300831-99-6P
(preparation of macrocyclic peptides active against the hepatitis C virus)
IT 300831-95-2P
(preparation of macrocyclic peptides active against the hepatitis C virus)
RN 300831-95-2 USPATFULL
CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclotridecine-12a(5H)-carboxylic acid, 6-[[(1,1-dimethylethoxy)carbonyl]amino]-1,2,3,6,7,8,9,11a,12,13,14,14a-dodecahydro-2-[(7-methoxy-2-phenyl-4-quinolinyl)oxy]-5,14-dioxo-, (2R,6S,10E,11aR,12aR,14aS)- (CA INDEX NAME)

STRUCTURE DIAGRAM IS NOT AVAILABLE

L35 ANSWER 16 OF 26 USPATFULL on STN
AN 2002:16828 USPATFULL
TI REAGENTS AND METHODS FOR THE DETECTION AND QUANTIFICATION OF VANCOMYCIN IN BIOLOGICAL FLUIDS
IN ADAMCZYK, MACIEJ, GURNEE, IL, UNITED STATES
BRATE, ELAINE M., GRAYSLAKE, IL, UNITED STATES
PERKOWITZ, MARY M., LAKE ZURICH, IL, UNITED STATES
REGE, SUSHIL D., GURNEE, IL, UNITED STATES
PI US-20020009708 A1 20020124 <--
US-----6797479 B2 20040928
AI 1998US-000174121 A1 19981016 (9) <--
RLI Continuation-in-part of Ser. No. 1998US-000026869, filed on 20 Feb 1998, ABANDONED Continuation of Ser. No. 1995US-000416567, filed on 4 Apr 1995, ABANDONED
DT Utility
FS APPLICATION
LREP ABBOTT LABORATORIES, DEPT. 377 - AP6D-2, 100 ABBOTT PARK ROAD, ABBOTT PARK, IL, 60064-6050
CLMN Number of Claims: 39
ECL Exemplary Claim: 1
DRWN 26 Drawing Page(s)
LN.CNT 1619
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Immunoassay reagents, methods and test kits for the specific quantification of vancomycin in a test sample are disclosed. The reagent comprises antibodies prepared with immunogens of FIG. 6 wherein P is an immunogenic carrier material and X is a linking moiety.

Also described is the synthesis of labeled reagents of FIG. 8 wherein Q is a detectable moiety, preferably fluorescein or a fluorescein derivative, and X is a linking moiety.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 224826-26-0P 224826-28-2P 224826-31-7P
(immunoassay reagents and methods and test kits for detection and quantification of vancomycin in biol. fluids)
IT 224826-26-0P
(immunoassay reagents and methods and test kits for detection and quantification of vancomycin in biol. fluids)
RN 224826-26-0 USPATFULL
CN Vancomycin, N3''-[4-[[(4-methylphenyl)sulfonyl][10-(3-sulfopropyl)acridinium-9-yl]carbonyl]amino]-1-oxobutyl]-, inner salt (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



L35 ANSWER 16 OF 26 USPATFULL on STN (Continued)

PAGE 1-B



PAGE 2-A

PAGE 2-B



L35 ANSWER 17 OF 26 USPATFULL on STN
AN 2000:80846 USPATFULL
TI Peptidomimetic of helix-turn-helix or gamma-turn
IN Etzkorn, Felicia A., Charlottesville, VA, United States
Travins, Jeremy M., Charlottesville, VA, United States
PA University of Virginia Patent Foundation, Charlottesville, VA, United States (U.S. corporation)
PI US-----6080838 20000627 <--
AI 1997US-000978023 19971125 (8) <--
DT Utility
FS Granted
EXNAM Primary Examiner: Tsang, Cecilia J.; Assistant Examiner: Jameison, Fabian A.
LREP Oblon, Spivak, McClelland, Maier & Neustadt, P.C.
CLMN Number of Claims: 5
ECL Exemplary Claim: 1
DRWN 4 Drawing Figure(s); 4 Drawing Page(s)
LN.CNT 774
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A peptidomimetic of the turn in the helix-turn-helix (HTH) motif of DNA-binding proteins was designed and synthesized. Conformational constraint was achieved by an unusual linking of two amino acids with a side-chain carbon--carbon bond. A phenyl ring provides the potential for new hydrophobic contacts with the hydrophobic core of the HTH motif. In the mimic, the peptide backbone and the central residue were retained in native form within a 12-membered cyclic tripeptide. The target compound 1b was synthesized by two sequential Horner-Wittig couplings followed by enantioselective hydrogenation with Rh(MeDuPHOS) in 8 steps and 35% overall yield. The stereochemical outcome of the key hydrogenation was determined by aromatic ring oxidation with RuO.sub.2 /NaIO.sub.4 to give two equivalents of Boc-Asp-OMe.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 196860-92-1P
(preparation of peptidomimetic of helix-turn-helix or gamma-turn)
IT 196860-92-1P
(preparation of peptidomimetic of helix-turn-helix or gamma-turn)
RN 196860-92-1 USPATFULL
CN 4,7-Diazabicyclo[9.3.1]pentadeca-1(15),11,13-triene-3-carboxylic acid, 9-[[(1,1-dimethylethoxy)carbonyl]amino]-5,8-dioxo-, (3S,9S)- (CA INDEX NAME)



L35 ANSWER 18 OF 26 USPATFULL on STN
AN 1999:137211 USPATFULL
TI Glycopeptide antibiotic derivatives
IN Cooper, Robin D. G., Indianapolis, IN, United States
Huff, Bret E., Mooresville, IN, United States
Nicas, Thalia I., Indianapolis, IN, United States
Quatroche, John T., Indianapolis, IN, United States
Rodriguez, Michael J., Indianapolis, IN, United States
Snyder, Nancy J., Charlottesville, IN, United States
Staszak, Michael A., Indianapolis, IN, United States
Thompson, Richard C., Frankfort, IN, United States
Wilkie, Stephen C., Indianapolis, IN, United States
Zweifel, Mark J., Indianapolis, IN, United States
PA Eli Lilly and Company, Indianapolis, IN, United States (U.S. corporation)
PI US-----5977062 19991102 <--
AI 1998US-000062235 19980417 (9) <--
RLI Continuation of Ser. No. 199SUS-000410155, filed on 24 Mar 1995, now patented, Pat. No. US-----5840684 which is a continuation-in-part of Ser. No. 1994US-000356413, filed on 15 Dec 1994, now abandoned which is a continuation-in-part of Ser. No. 1994US-000189393, filed on 28 Jan 1994, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Tsang, Cecilia J.; Assistant Examiner: Gupta, Anish
LREP Musser, Arlene K.
CLMN Number of Claims: 34
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 4666
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides glycopeptide antibiotic derivative compounds. These derivative compounds possess antibacterial activity against a wide variety of bacteria, including activity against vancomycin-resistant isolates. Methods of making and using these glycopeptide antibiotic derivative compounds are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 171097-54-4P 171097-56-6P 171097-59-9P
171097-60-2P 171097-61-3P 171097-86-2P
171098-89-8P 171099-48-2P
(preparation of glycopeptide antibiotic derivs.)
IT 171097-54-4P
(preparation of glycopeptide antibiotic derivs.)
RN 171097-54-4 USPATFULL
CN Vancomycin, 22-O-(3-amino-2,3,6-trideoxy-3-C-methyl-a-L-arabino-hexopyranosyl)-N3''-(9-phenanthrenylmethyl)-, (4''R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L35 ANSWER 18 OF 26 USPATFULL on STN (Continued)

PAGE 1-A



PAGE 1-B



PAGE 2-A



L35 ANSWER 18 OF 26 USPATFULL on STN (Continued)

PAGE 2-B



L35 ANSWER 19 OF 26 USPATFULL on STN
AN 1998:150893 USPATFULL
TI Glycopeptide antibiotic derivatives
IN Cooper, Robin D. G., Indianapolis, IN, United States
Huff, Bret E., Mooresville, IN, United States
Nicas, Thalia I., Indianapolis, IN, United States
Quatroche, John T., Indianapolis, IN, United States
Rodriguez, Michael J., Indianapolis, IN, United States
Snyder, Nancy J., Charlottesville, IN, United States
Staszak, Michael A., Indianapolis, IN, United States
Thompson, Richard C., Frankfort, IN, United States
Wilkie, Stephen C., Indianapolis, IN, United States
Zweifel, Mark J., Indianapolis, IN, United States
PA Eli Lilly and Company, Indianapolis, IN, United States (U.S. corporation)
PI US-----5843889 19981201 <--
AI 1997US-000816224 19970312 (8) <--
RLI Division of Ser. No. 1994US-000356413, filed on 15 Dec 1994, now abandoned which is a continuation-in-part of Ser. No. 1994US-000189393, filed on 28 Jan 1994, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Tsang, Cecilia J.; Assistant Examiner: Marshall, S. G.
LREP Page, Kathleen R. S., Boone, David E.
CLMN Number of Claims: 9
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 2070
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides glycopeptide antibiotic derivative compounds. These derivative compounds possess antibacterial activity aginst a wide variety of bacteria, including activity against vancomycin-resistant isolates. Methods of making and using these glycopeptide antibiotic derivative compounds are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 171097-54-4P 171097-56-6P 171097-59-9P
171097-60-2P 171097-61-3P 171097-86-2P
171098-89-8P 171099-48-2P
(preparation of glycopeptide antibiotic derivs.)
IT 171097-54-4P
(preparation of glycopeptide antibiotic derivs.)
RN 171097-54-4 USPATFULL
CN Vancomycin, 22-O-(3-amino-2,3,6-trideoxy-3-C-methyl-α-L-arabino-hexopyranosyl)-N3''-(9-phenanthrenylmethyl)-, (4''R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L35 ANSWER 19 OF 26 USPATFULL on STN (Continued)

PAGE 1-A



PAGE 1-B



L35 ANSWER 19 OF 26 USPATFULL on STN (Continued)

PAGE 2-A



PAGE 2-B



L35 ANSWER 20 OF 26 USPATFULL on STN
AN 1998:147402 USPATFULL
TI Glycopeptide antibiotic derivatives
IN Cooper, Robin D. G., Indianapolis, IN, United States
Huff, Bret E., Mooresville, IN, United States
Nicas, Thalia I., Indianapolis, IN, United States
Quatroche, John T., Indianapolis, IN, United States
Rodriguez, Michael J., Indianapolis, IN, United States
Snyder, Nancy J., Charlottesville, IN, United States
Staszak, Michael A., Indianapolis, IN, United States
Thompson, Richard C., Frankfort, IN, United States
Wilkie, Stephen C., Indianapolis, IN, United States
Zweifel, Mark J., Indianapolis, IN, United States
PA Eli Lilly and Company, Indianapolis, IN, United States (U.S. corporation)
PI US-----5840684 19981124 <--
AI 1995US-000410155 19950324 (8) <--
RLI Continuation-in-part of Ser. No. 1994US-000356413, filed on 15 Dec 1994, now abandoned which is a continuation-in-part of Ser. No. 1994US-000189393, filed on 28 Jan 1994, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Tsang, Cecilia J.; Assistant Examiner: Gupta, Anish
LREP Page, Kathleen R. S., Plant, Thomas G., Boone, David E.
CLMN Number of Claims: 7
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 2201
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides glycopeptide antibiotic derivative compounds. These derivative compounds possess antibacterial activity against a wide variety of bacteria, including activity against vancomycin-resistant isolates. Methods of making and using these glycopeptide antibiotic derivative compounds are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 171097-54-4P 171097-56-6P 171097-59-9P
171097-60-2P 171097-61-3P 171097-86-2P
171098-89-8P 171099-48-2P 183669-54-7P
183669-74-1P 183669-75-2P
(preparation of 4-(4-chlorophenyl)benzyl-A 82846B and related compds. as antibiotics)
IT 171097-54-4P
(preparation of 4-(4-chlorophenyl)benzyl-A 82846B and related compds. as antibiotics)
RN 171097-54-4 USPATFULL
CN Vancomycin, 22-O-(3-amino-2,3,6-trideoxy-3-C-methyl-α-L-arabino-hexopyranosyl)-N3''-(9-phenanthrenylmethyl)-, (4''R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L35 ANSWER 20 OF 26 USPATFULL on STN (Continued)

PAGE 1-A



PAGE 1-B



L35 ANSWER 20 OF 26 USPATFULL on STN (Continued)

PAGE 2-A



PAGE 2-B



L35 ANSWER 21 OF 26 USPATFULL on STN

AN 91:92638 USPATFULL
TI Cyclic GnRH antagonists
IN Rivier, Jean E. F., La Jolla, CA, United States
Koerber, Steven C., Encinitas, CA, United States
Hagler, Arnold T., La Jolla, CA, United States
Rivier, Catherine L., La Jolla, CA, United States
Vale, Jr., Wylie W., La Jolla, CA, United States
PA The Salk Institute for Biological Studies, San Diego, CA, United States (U.S. corporation)
PI US-----5064939 19911112 <--
AI 1990US-000475767 19900206 (7) <--
DT Utility
FS Granted
EXNAM Primary Examiner: Lee, Lester L.; Assistant Examiner: Davenport, Avis
LREP Fitch, Even, Tabin & Flannery
CLMN Number of Claims: 35
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1277
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Peptides which inhibit the secretion of gonadotropins by the pituitary gland and inhibit the release of steroids by the gonads. Administration of an effective amount of such GnRH antagonists prevents ovulation of female mammalian eggs and/or the release of steroids by the gonads. These peptides may be used to treat steroid-dependent tumors, such as prostatic and mammary tumors. The peptides include cyclic, bicyclic and tricyclic analogs of the decapeptide GnRH, and preferably there are at least two covalent bonds between the residues in the 4- and 10-positions, the residues in the 5- and 8-positions and the residues in the 1- and 3-positions, respectively. Examples of such bonds include a disulfide linkage between Cys residues, an amide linkage between a side chain amino group and a side chain carboyxl group, a dicarba linkage between side-chain alkyl groups, and a carba linkage between a side-chain alkyl group and a side-chain sulfhydryl group.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 137210-54-9P 137210-55-0P 137210-57-2P
137210-59-4P 137255-30-2P 137267-90-4P
137267-91-5P 138954-39-9P 138954-43-5P
(preparation of, as gonadotropin-releasing hormone antagonist)
IT 137210-54-9P
(preparation of, as gonadotropin-releasing hormone antagonist)
RN 137210-54-9 USPATFULL
CN Glycinamide, 4-chloro-D-phenylalanyl-N11-acetyl(R)-11-carboxy-D-2,11-diaminoundecanoyl-L-ornithyl-L-tyrosyl-3-(2-naphthalenyl)-D-alanyl-L-leucyl-N5-[(diethylamino)iminomethyl]-L-ornithyl-L-prolyl-, cyclic (2→1)-peptide (9CI) (CA INDEX NAME)

PAGE 1-A



L35 ANSWER 21 OF 26 USPATFULL on STN (Continued)

PAGE 1-B



L35 ANSWER 22 OF 26 USPAT2 on STN

AN 2007:69257 USPAT2
TI Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors
IN Nakajima, Suanne, Cambridge, MA, UNITED STATES
Miao, Zhenwei, Medway, MA, UNITED STATES
Sun, Ying, Waltham, MA, UNITED STATES
Tang, Datong, Malden, MA, UNITED STATES
Xu, Gouyou, Auburndale, MA, UNITED STATES
Porter, Brian, Cambridge, MA, UNITED STATES
Or, Yat Sun, Watertown, MA, UNITED STATES
Wang, Zhe, Hockessin, DE, UNITED STATES
PA Enanta Pharmaceuticals, Inc., Watertown, MA, UNITED STATES (U.S. corporation)
PI US-----7368452 B2 20080506
AI 2006US-000489011 20060718 (11)
RLI Continuation of Ser. No. 2004US-000826743, filed on 16 Apr 2004, Pat. No. US-----7176208
PRAI 2003US-000509071P 20030418 (60) <--
DT Utility
FS GRANTED
EXNAM Primary Examiner: Kifle, Bruck
LREP Nukajima, Suanne, Elmore, Carolyn S., Elmore Patent Law Group
CLMN Number of Claims: 12
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 3984
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to compounds of Formula I or II, or a pharmaceutically acceptable salt, ester, or prodrug, thereof:

##STR1## which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 787600-38-8P
(preparation of quinoxalinyl cyclic peptides as hepatitis C serine protease inhibitors)
IT 787600-38-8P
(preparation of quinoxalinyl cyclic peptides as hepatitis C serine protease inhibitors)
RN 787600-38-8 USPAT2
CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[(1,1-dimethylethoxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-2-[[3-(2-thienyl)benzo[g]quinoxalin-2-yl]oxy]-, (2R,6S,13aS,14aR,16aS)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.

L35 ANSWER 22 OF 26 USPAT2 on STN (Continued)

PAGE 1-A



PAGE 1-B



PAGE 2-B

L35 ANSWER 23 OF 26 USPAT2 on STN

AN 2005:88018 USPAT2
TI Glycopeptide antibiotics, combinational libraries of glycopeptide antibiotics and methods of producing same
IN Kahne, Daniel, Princeton, NJ, UNITED STATES
Kerns, Robert, Troy, MI, UNITED STATES
Fukuzawa, Seketsu, Tokyo, JAPAN
Ge, Min, Princeton, NJ, UNITED STATES
Thompson, Christopher, Milford, MA, UNITED STATES
PA The Trustees of Princeton University, Princeton, NJ, UNITED STATES (U.S. corporation)
PI US-----7331920 B2 20080219
AI 2003US-000676391 20031001 (10) <--
RLI Division of Ser. No. 1999US-000353368, filed on 14 Jul 1999, Pat. No. US-----6710168
PRAI 1999US-000134839P 19990519 (60) <--
1998US-000150690P 19980714 (60) <--
DT Utility
FS GRANTED
EXNAM Primary Examiner: Schultz, J. Douglas; Assistant Examiner: Lundgren, J. S.
LREP Woodcock Washburn, LLP
CLMN Number of Claims: 8
ECL Exemplary Claim: 1
DRWN 26 Drawing Figure(s); 26 Drawing Page(s)
LN.CNT 4055
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Methods for preparing a glycopeptide are disclosed. The methods comprise the steps of selecting a protected glycopeptide of the formula A.sub.1-A.sub.2-A.sub.3-A.sub.4-A.sub.5-A.sub.6-A.sub.7, wherein the groups A.sub.1 to A.sub.7 comprise the heptapeptide structure of naturally occurring vancomycin; at least A.sub.4 is linked to a glycosidic group which has a hexose residue linked to A.sub.4; and the protected glycopeptide has no free amino or carboxyl groups and has a free primary hydroxyl group only at the 6-position of said hexose residue. The protected glycopeptide is contacted with a compound of the formula ArSO.sub.2G where Ar is an aryl group and G is a leaving group under conditions effective to allow reaction of said free primary hydroxyl group to form a glycopeptide sulfonate ester; and the glycopeptide sulfonate ester is contacted with a nucleophile under conditions effective to allow displacement of a sulfonate group to produce a substituted glycopeptide.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 256350-24-0P
(preparation of glycopeptide antibiotics and their combinatorial libraries)
IT 256350-24-0P
(preparation of glycopeptide antibiotics and their combinatorial libraries)
RN 256350-24-0 USPAT2
CN Vancomycin, 6'-deoxy-6'-[(2-pyrenylsulfonyl)oxy]-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 256350-23-9
CMF C82 H83 Cl2 N9 O26 S

Absolute stereochemistry.

L35 ANSWER 23 OF 26 USPAT2 on STN (Continued)

PAGE 1-A



PAGE 1-B



PAGE 2-A



L35 ANSWER 23 OF 26 USPAT2 on STN (Continued)

PAGE 2-B



PAGE 3-B

CM 2

CRN 76-05-1
CMF C2 H F3 O2

L35 ANSWER 24 OF 26 USPAT2 on STN
AN 2004:335576 USPAT2
TI Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors
IN Nakajima, Suanne, Cambridge, MA, UNITED STATES
Miao, Zhenwei, Medway, MA, UNITED STATES
Sun, Ying, Waltham, MA, UNITED STATES
Tang, Datong, Malden, MA, UNITED STATES
Xu, Guoyou, Auburndale, MA, UNITED STATES
Porter, Brian, Cambridge, MA, UNITED STATES
Or, Yat Sun, Watertown, MA, UNITED STATES
Wang, Zhe, Hockessin, DE, UNITED STATES
PA Enanta Pharmaceuticals, Inc., Watertown, MA, UNITED STATES (U.S. corporation)
PI US-----7176208 B2 20070213
AI 2004US-0008826743 20040416 (10) <--
PRAI 2003US-000509071P 20030418 (60) <--
DT Utility
FS GRANTED
EXNAM Primary Examiner: Kifle, Bruck
LREP Edwards Angell Palmer & Dodge LLP, Hsi, Jeffrey D.
CLMN Number of Claims: 10
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 3906
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to compounds of Formula I or II, or a pharmaceutically acceptable salt, ester, or prodrug, thereof:

##STR1## which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 787600-38-8P
(preparation of quinoxalinyl cyclic peptides as hepatitis C serine protease inhibitors)
IT 787600-38-8P
(preparation of quinoxalinyl cyclic peptides as hepatitis C serine protease inhibitors)
RN 787600-38-8 USPAT2
CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[(1,1-dimethylethoxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-2-[[3-(2-thienyl)benzo[g]quinoxalin-2-yl]oxy]-, (2R,6S,13aS,14aR,16aS)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.

L35 ANSWER 24 OF 26 USPAT2 on STN (Continued)

PAGE 1-A



PAGE 1-B



PAGE 2-B

L35 ANSWER 25 OF 26 USPAT2 on STN
AN 2004:51441 USPAT2
TI Inhibitors of hepatitis C virus
IN Campbell, Jeffrey Allen, Cheshire, CT, United States
Good, Andrew Charles, Wallingford, CT, United States
PA Bristol-Myers Squibb Company, Princeton, NJ, United States (U.S. corporation)
PI US-----6867185 B2 20050315
AI 2002US-0003317451 20021212 (10) <--
PRAI 2002US-0003822103P 20020520 (60) <--
2001US-0003440080P 20011220 (60) <--
DT Utility
FS GRANTED
EXNAM Primary Examiner: Leith, Patricia; Assistant Examiner: Audet, Maury
CLMN Number of Claims: 14
ECL Exemplary Claim: 1
DRWN 0 Drawing Figure(s); 0 Drawing Page(s)
LN.CNT 4354
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to macrocyclic compounds, methods for making these compounds, pharmaceutical compositions and the therapeutic or prophylactic use of these compounds by administering said compounds to mammals or treat hepatitis C virus (HCV) infection.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 552334-90-4P 552334-92-6P
(preparation of macrocyclic compds. as inhibitors of hepatitis C virus)
IT 552334-91-5P 552334-93-7P
(preparation of macrocyclic compds. as inhibitors of hepatitis C virus)
IT 552335-27-0P 552335-30-5P
(preparation of macrocyclic compds. as inhibitors of hepatitis C virus)
IT 552334-90-4P
(preparation of macrocyclic compds. as inhibitors of hepatitis C virus)
RN 552334-90-4 USPAT2
CN Carbamic acid, [(2R,6S,9E,10aS,11aR,13aS)-11a-[[(cyclopropylsulfonyl)amino]carbonyl]-2,3,5,6,7,8,10a,11,11a,12,13,13a-dodecahydro-2-[(7-methoxy-2-phenyl-4-quinolinyl)oxy]-5,13-dioxo-1H-cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclododecin-6-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



L35 ANSWER 26 OF 26 USPAT2 on STN

AN 2002:16828 USPAT2

TI Reagents and methods for the detection and quantification of vancomycin in biological fluids

IN Adamczyk, Maciej, Gurnee, IL, United States
Brate, Elaine M., Grayslake, IL, United States
Perkowitz, Mary M., Lake Zurich, IL, United States
Rege, Sushil D., Gurnee, IL, United States

PA Abbott Laboratories, Abbott Park, IL, United States (U.S. corporation)

PI US-----6797479 B2 20040928 <--

AI 1998US-000174121 19981016 (9) <--

RLI Continuation-in-part of Ser. No. 1998US-000026869, filed on 20 Feb 1998, now abandoned Continuation of Ser. No. 1995US-000416567, filed on 4 Apr 1995, now abandoned

DT Utility

FS GRANTED

EXNAM Primary Examiner: Ponnaluri, Padmashri

LREP Anderson, Regina M.

CLMN Number of Claims: 9

ECL Exemplary Claim: 1

DRWN 27 Drawing Figure(s); 26 Drawing Page(s)

LN.CNT 1493

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Immunoassay reagents, methods and test kits for the specific quantification of vancomycin in a test sample are disclosed. The reagent comprises antibodies prepared with immunogens of FIG. 6 wherein P is an immunogenic carrier material and X is a linking moiety. Also described is the synthesis of labeled reagents of FIG. 8 wherein Q is a detectable moiety, preferably fluorescein or a fluorescein derivative, and X is a linking moiety.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 224826-26-0P 224826-28-2P 224826-31-7P
(immunoassay reagents and methods and test kits for detection and quantification of vancomycin in biol. fluids)

IT 224826-26-0P
(immunoassay reagents and methods and test kits for detection and quantification of vancomycin in biol. fluids)

RN 224826-26-0 USPAT2

CN Vancomycin, N3''-[4-[[(4-methylphenyl)sulfonyl][10-(3-sulfopropyl)acridinium-9-yl]carbonyl]amino]-1-oxobutyl]-, inner salt (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



L35 ANSWER 26 OF 26 USPAT2 on STN (Continued)

PAGE 1-B



PAGE 2-A

Cl

PAGE 2-B



```
=> d his

     (FILE 'HOME' ENTERED AT 10:39:24 ON 23 SEP 2008)

     FILE 'HCAPLUS' ENTERED AT 10:39:54 ON 23 SEP 2008
L1            1 US20070072792/PN

     FILE 'REGISTRY' ENTERED AT 10:40:09 ON 23 SEP 2008

     FILE 'HCAPLUS' ENTERED AT 10:40:09 ON 23 SEP 2008
L2               TRA L1 1- RN :      311 TERMS

     FILE 'REGISTRY' ENTERED AT 10:40:09 ON 23 SEP 2008
L3           311 SEA L2

     FILE 'REGISTRY' ENTERED AT 10:40:15 ON 23 SEP 2008
L4               STR
L5             3 L4
L6       1987968 14-17/RATC
L7             1 L4 SAM SUB=L6
L8           698 L4 FULL SUB=L6
                 SAV TEM J260C1GIV/A L8
L9            40 L8 AND L3
L10          658 L8 NOT L9
L11           60 L10 AND C3/EAS
L12              STR L4
L13            0 L12 SAM SUB=L8
L14            0 L12 FULL SUB=L8
L15          293 L10 AND NRRS=1
L16           39 L9 AND NRRS=1
L17            1 L9 NOT L16

     FILE 'HCAPLUS' ENTERED AT 11:01:25 ON 23 SEP 2008
L18            2 L16

     FILE 'REGISTRY' ENTERED AT 11:02:27 ON 23 SEP 2008
L19              STR L4
L20            8 L19 SAM SUB=L8
L21          188 L19 FULL SUB=L8
                 SAV TEM J260C1GIVS/A L21
L22           39 L21 AND L3
L23          149 L21 NOT L22

     FILE 'HCAPLUS' ENTERED AT 11:05:00 ON 23 SEP 2008
L24            2 L22
L25           48 L23
L26           31 L25 AND (PRD<=20041104 OR PD<=20041104 OR AD<=20041104)
                 SEL HIT RN

     FILE 'REGISTRY' ENTERED AT 11:06:15 ON 23 SEP 2008
L27           66 E1-66
L28            3 L27 AND (C22H39N3O5 OR C22H41N3O5 OR C40H47N5O9S)
                 SEL RN 2-3
L29            2 E67-68 AND L28

     FILE 'HCAPLUS' ENTERED AT 11:17:27 ON 23 SEP 2008
L30            1 L29

     FILE 'HCAOLD' ENTERED AT 11:17:40 ON 23 SEP 2008
L31            0 L22
L32            0 L23

     FILE 'USPATFULL, USPATOLD, USPAT2' ENTERED AT 11:18:30 ON 23 SEP 2008
L33            1 L22
L34           34 L23
L35           26 L34 AND (PRD<=20041104 OR PD<=20041104 OR AD<=20041104)
L36            0 L29

     FILE 'HCAPLUS' ENTERED AT 11:20:38 ON 23 SEP 2008
```

L37 2 L18,L24
L38 2 L18,L24

=>